{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 116,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "from bs4 import BeautifulSoup\n",
    "import pandas as pd\n",
    "import re\n",
    "import altair as alt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 117,
   "metadata": {},
   "outputs": [],
   "source": [
    "ftr= pd.read_csv('./final_tracking.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 118,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>Lab</th>\n",
       "      <th>Study explanation</th>\n",
       "      <th>Study title</th>\n",
       "      <th>Phase</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>MAPS PBC</td>\n",
       "      <td>MAPS has completed conducting two Phase 3 tria...</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)  |  MDMA</td>\n",
       "      <td>Phase 3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>Compass Pathways</td>\n",
       "      <td>COMP360 is a psilocybin formulation currently ...</td>\n",
       "      <td>Treatment-resistant depression (TRD)  |  COMP3...</td>\n",
       "      <td>Phase 3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>Awakn Life Sciences</td>\n",
       "      <td>Awakn is set to evaluate ketamine-assisted psy...</td>\n",
       "      <td>Alcohol use disorder (AUD)  |  Ketamine</td>\n",
       "      <td>Phase 3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>GH Research</td>\n",
       "      <td>GH001 is an inhaled formulation of 5-MeO-DMT, ...</td>\n",
       "      <td>Treatment-resistant depression (TRD)| GH001 (5...</td>\n",
       "      <td>Phase 2b</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>MindMed</td>\n",
       "      <td>MM-120 is a formulation of LSD being evaluated...</td>\n",
       "      <td>Generalized Anxiety Disorder (GAD)  | MM-120 (...</td>\n",
       "      <td>Phase 2b</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>83</td>\n",
       "      <td>PSYLO</td>\n",
       "      <td>Psylo is currently in the discovery stages of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>84</td>\n",
       "      <td>Mindstate Design</td>\n",
       "      <td>MSD-101, MSD-102, MSD-103, MSD-104, MSD-105 Di...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>85</td>\n",
       "      <td>Lusaris Therapeutics</td>\n",
       "      <td>Lusaris is developing a portfolio of new compo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>86</td>\n",
       "      <td>Beckley Psytech</td>\n",
       "      <td>NCE discovery program.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>87</td>\n",
       "      <td>Onsero</td>\n",
       "      <td>Onsero is developing a portfolio of unknown 5-...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>88 rows Ã— 5 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    Unnamed: 0                    Lab  \\\n",
       "0            0               MAPS PBC   \n",
       "1            1      Compass Pathways    \n",
       "2            2    Awakn Life Sciences   \n",
       "3            3            GH Research   \n",
       "4            4               MindMed    \n",
       "..         ...                    ...   \n",
       "83          83                 PSYLO    \n",
       "84          84       Mindstate Design   \n",
       "85          85  Lusaris Therapeutics    \n",
       "86          86       Beckley Psytech    \n",
       "87          87                Onsero    \n",
       "\n",
       "                                    Study explanation  \\\n",
       "0   MAPS has completed conducting two Phase 3 tria...   \n",
       "1   COMP360 is a psilocybin formulation currently ...   \n",
       "2   Awakn is set to evaluate ketamine-assisted psy...   \n",
       "3   GH001 is an inhaled formulation of 5-MeO-DMT, ...   \n",
       "4   MM-120 is a formulation of LSD being evaluated...   \n",
       "..                                                ...   \n",
       "83  Psylo is currently in the discovery stages of ...   \n",
       "84  MSD-101, MSD-102, MSD-103, MSD-104, MSD-105 Di...   \n",
       "85  Lusaris is developing a portfolio of new compo...   \n",
       "86                             NCE discovery program.   \n",
       "87  Onsero is developing a portfolio of unknown 5-...   \n",
       "\n",
       "                                          Study title      Phase  \n",
       "0      Post-traumatic stress disorder (PTSD)  |  MDMA    Phase 3  \n",
       "1   Treatment-resistant depression (TRD)  |  COMP3...    Phase 3  \n",
       "2             Alcohol use disorder (AUD)  |  Ketamine    Phase 3  \n",
       "3   Treatment-resistant depression (TRD)| GH001 (5...   Phase 2b  \n",
       "4   Generalized Anxiety Disorder (GAD)  | MM-120 (...   Phase 2b  \n",
       "..                                                ...        ...  \n",
       "83                                                NaN        NaN  \n",
       "84                                                NaN        NaN  \n",
       "85                                                NaN        NaN  \n",
       "86                                                NaN        NaN  \n",
       "87                                                NaN        NaN  \n",
       "\n",
       "[88 rows x 5 columns]"
      ]
     },
     "execution_count": 118,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ftr"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 119,
   "metadata": {},
   "outputs": [],
   "source": [
    "ftr['health issue'] = ftr['Study title'].str.extract(r'(\\w.*)\\|')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 120,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>Lab</th>\n",
       "      <th>Study explanation</th>\n",
       "      <th>Study title</th>\n",
       "      <th>Phase</th>\n",
       "      <th>health issue</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>MAPS PBC</td>\n",
       "      <td>MAPS has completed conducting two Phase 3 tria...</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)  |  MDMA</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>Compass Pathways</td>\n",
       "      <td>COMP360 is a psilocybin formulation currently ...</td>\n",
       "      <td>Treatment-resistant depression (TRD)  |  COMP3...</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>Awakn Life Sciences</td>\n",
       "      <td>Awakn is set to evaluate ketamine-assisted psy...</td>\n",
       "      <td>Alcohol use disorder (AUD)  |  Ketamine</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Alcohol use disorder (AUD)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>GH Research</td>\n",
       "      <td>GH001 is an inhaled formulation of 5-MeO-DMT, ...</td>\n",
       "      <td>Treatment-resistant depression (TRD)| GH001 (5...</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>MindMed</td>\n",
       "      <td>MM-120 is a formulation of LSD being evaluated...</td>\n",
       "      <td>Generalized Anxiety Disorder (GAD)  | MM-120 (...</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>Generalized Anxiety Disorder (GAD)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>83</td>\n",
       "      <td>PSYLO</td>\n",
       "      <td>Psylo is currently in the discovery stages of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>84</td>\n",
       "      <td>Mindstate Design</td>\n",
       "      <td>MSD-101, MSD-102, MSD-103, MSD-104, MSD-105 Di...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>85</td>\n",
       "      <td>Lusaris Therapeutics</td>\n",
       "      <td>Lusaris is developing a portfolio of new compo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>86</td>\n",
       "      <td>Beckley Psytech</td>\n",
       "      <td>NCE discovery program.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>87</td>\n",
       "      <td>Onsero</td>\n",
       "      <td>Onsero is developing a portfolio of unknown 5-...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>88 rows Ã— 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    Unnamed: 0                    Lab  \\\n",
       "0            0               MAPS PBC   \n",
       "1            1      Compass Pathways    \n",
       "2            2    Awakn Life Sciences   \n",
       "3            3            GH Research   \n",
       "4            4               MindMed    \n",
       "..         ...                    ...   \n",
       "83          83                 PSYLO    \n",
       "84          84       Mindstate Design   \n",
       "85          85  Lusaris Therapeutics    \n",
       "86          86       Beckley Psytech    \n",
       "87          87                Onsero    \n",
       "\n",
       "                                    Study explanation  \\\n",
       "0   MAPS has completed conducting two Phase 3 tria...   \n",
       "1   COMP360 is a psilocybin formulation currently ...   \n",
       "2   Awakn is set to evaluate ketamine-assisted psy...   \n",
       "3   GH001 is an inhaled formulation of 5-MeO-DMT, ...   \n",
       "4   MM-120 is a formulation of LSD being evaluated...   \n",
       "..                                                ...   \n",
       "83  Psylo is currently in the discovery stages of ...   \n",
       "84  MSD-101, MSD-102, MSD-103, MSD-104, MSD-105 Di...   \n",
       "85  Lusaris is developing a portfolio of new compo...   \n",
       "86                             NCE discovery program.   \n",
       "87  Onsero is developing a portfolio of unknown 5-...   \n",
       "\n",
       "                                          Study title      Phase  \\\n",
       "0      Post-traumatic stress disorder (PTSD)  |  MDMA    Phase 3   \n",
       "1   Treatment-resistant depression (TRD)  |  COMP3...    Phase 3   \n",
       "2             Alcohol use disorder (AUD)  |  Ketamine    Phase 3   \n",
       "3   Treatment-resistant depression (TRD)| GH001 (5...   Phase 2b   \n",
       "4   Generalized Anxiety Disorder (GAD)  | MM-120 (...   Phase 2b   \n",
       "..                                                ...        ...   \n",
       "83                                                NaN        NaN   \n",
       "84                                                NaN        NaN   \n",
       "85                                                NaN        NaN   \n",
       "86                                                NaN        NaN   \n",
       "87                                                NaN        NaN   \n",
       "\n",
       "                               health issue  \n",
       "0   Post-traumatic stress disorder (PTSD)    \n",
       "1    Treatment-resistant depression (TRD)    \n",
       "2              Alcohol use disorder (AUD)    \n",
       "3      Treatment-resistant depression (TRD)  \n",
       "4      Generalized Anxiety Disorder (GAD)    \n",
       "..                                      ...  \n",
       "83                                      NaN  \n",
       "84                                      NaN  \n",
       "85                                      NaN  \n",
       "86                                      NaN  \n",
       "87                                      NaN  \n",
       "\n",
       "[88 rows x 6 columns]"
      ]
     },
     "execution_count": 120,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ftr"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 121,
   "metadata": {},
   "outputs": [],
   "source": [
    "ftr['Lead substance'] = ftr['Study title'].str.extract(r'\\|\\s(.*)')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 122,
   "metadata": {},
   "outputs": [],
   "source": [
    "#ftr['Product substance'] = ftr['Study title'].str.extract(r'\\((\\w+)\\)[^\\)]*$')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 123,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>Lab</th>\n",
       "      <th>Study explanation</th>\n",
       "      <th>Study title</th>\n",
       "      <th>Phase</th>\n",
       "      <th>health issue</th>\n",
       "      <th>Lead substance</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>MAPS PBC</td>\n",
       "      <td>MAPS has completed conducting two Phase 3 tria...</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)  |  MDMA</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)</td>\n",
       "      <td>MDMA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>Compass Pathways</td>\n",
       "      <td>COMP360 is a psilocybin formulation currently ...</td>\n",
       "      <td>Treatment-resistant depression (TRD)  |  COMP3...</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "      <td>COMP360 (Psilocybin)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>Awakn Life Sciences</td>\n",
       "      <td>Awakn is set to evaluate ketamine-assisted psy...</td>\n",
       "      <td>Alcohol use disorder (AUD)  |  Ketamine</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Alcohol use disorder (AUD)</td>\n",
       "      <td>Ketamine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>GH Research</td>\n",
       "      <td>GH001 is an inhaled formulation of 5-MeO-DMT, ...</td>\n",
       "      <td>Treatment-resistant depression (TRD)| GH001 (5...</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "      <td>GH001 (5-MeO-DMT)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>MindMed</td>\n",
       "      <td>MM-120 is a formulation of LSD being evaluated...</td>\n",
       "      <td>Generalized Anxiety Disorder (GAD)  | MM-120 (...</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>Generalized Anxiety Disorder (GAD)</td>\n",
       "      <td>MM-120 (LSD)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>5</td>\n",
       "      <td>B More</td>\n",
       "      <td>SYNP-101 is a synthetic form of psilocybin bei...</td>\n",
       "      <td>Alcohol Use Disorder (AUD)  |  SYNP-101 (Psilo...</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>Alcohol Use Disorder (AUD)</td>\n",
       "      <td>SYNP-101 (Psilocybin)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>6</td>\n",
       "      <td>Apex Labs</td>\n",
       "      <td>APEX-52 is a low dose psilocybin formulation b...</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)| APEX-25...</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)</td>\n",
       "      <td>APEX-25 (Psilocybin)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>7</td>\n",
       "      <td>Perception Neuroscience</td>\n",
       "      <td>PCN-101 is arketamine (or R-ketamine), an isom...</td>\n",
       "      <td>Treatment-resistant depression (TRD)|  PCN-101...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "      <td>PCN-101 (R-ketamine)   (Complete)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>8</td>\n",
       "      <td>GH Research</td>\n",
       "      <td>GH001 is an inhaled formulation of 5-MeO-DMT, ...</td>\n",
       "      <td>Bipolar Disorder II (BDII)  |  GH001 (5-MeO-DM...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Bipolar Disorder II (BDII)</td>\n",
       "      <td>GH001 (5-MeO-DMT)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>9</td>\n",
       "      <td>GH Research</td>\n",
       "      <td>GH001 is an inhaled formulation of 5-MeO-DMT, ...</td>\n",
       "      <td>Postpartum Depression (PPD)  |  GH001 (5-MeO-D...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Postpartum Depression (PPD)</td>\n",
       "      <td>GH001 (5-MeO-DMT)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>10</td>\n",
       "      <td>Nova Mentis</td>\n",
       "      <td>NM-1001 is a low dose psilocybin formulation s...</td>\n",
       "      <td>Fragile X Syndrome  |  NM-1001 (Psilocybin)</td>\n",
       "      <td>Phase 2a</td>\n",
       "      <td>Fragile X Syndrome</td>\n",
       "      <td>NM-1001 (Psilocybin)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>11</td>\n",
       "      <td>Beckley Psytech</td>\n",
       "      <td>BPL-003 is an intranasal formulation of synthe...</td>\n",
       "      <td>Treatment-resistant depression (TRD)|  BPL-003...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "      <td>BPL-003 (5-MeO-DMT)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>12</td>\n",
       "      <td>MindMed</td>\n",
       "      <td>MM-110, also known as 18-MC or zolunicant, is ...</td>\n",
       "      <td>Opioid Withdrawal  | MM-110 (18-MC)</td>\n",
       "      <td>Phase 2a</td>\n",
       "      <td>Opioid Withdrawal</td>\n",
       "      <td>MM-110 (18-MC)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>13</td>\n",
       "      <td>MAPS PBC</td>\n",
       "      <td>MAPS is evaluating MDMA-assisted group therapy...</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)|  MDMA</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)</td>\n",
       "      <td>MDMA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>14</td>\n",
       "      <td>MAPS PBC</td>\n",
       "      <td>MAPS is evaluating MDMA-assisted psychotherapy...</td>\n",
       "      <td>Anorexia nervosa &amp; Binge eating disorder |  MD...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Anorexia nervosa &amp; Binge eating disorder</td>\n",
       "      <td>MDMA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>15</td>\n",
       "      <td>Usona Institute</td>\n",
       "      <td>The Usona Institute is currently evaluating ps...</td>\n",
       "      <td>Major Depressive Disorder (MDD)  |  Psilocybin</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Major Depressive Disorder (MDD)</td>\n",
       "      <td>Psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>16</td>\n",
       "      <td>Tryp Therapeutics</td>\n",
       "      <td>TRP-8802 is an orally-delivered synthetic psil...</td>\n",
       "      <td>Fibromyalgia  |  TRP-8802 (Psilocybin)</td>\n",
       "      <td>Phase 2a</td>\n",
       "      <td>Fibromyalgia</td>\n",
       "      <td>TRP-8802 (Psilocybin)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>17</td>\n",
       "      <td>Compass Pathways</td>\n",
       "      <td>COMP360 is a psilocybin formulation currently ...</td>\n",
       "      <td>Anorexia Nervosa  |  COMP360 (Psilocybin)</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Anorexia Nervosa</td>\n",
       "      <td>COMP360 (Psilocybin)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>18</td>\n",
       "      <td>Compass Pathways</td>\n",
       "      <td>COMP360 is a psilocybin formulation currently ...</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)|  COMP36...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)</td>\n",
       "      <td>COMP360 (Psilocybin)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>19</td>\n",
       "      <td>Braxia Scientific</td>\n",
       "      <td>Braxia is evaluating psilocybin-assisted thera...</td>\n",
       "      <td>Treatment-resistant depression (TRD)|  Psilocy...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "      <td>Psilocybin</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    Unnamed: 0                      Lab  \\\n",
       "0            0                 MAPS PBC   \n",
       "1            1        Compass Pathways    \n",
       "2            2      Awakn Life Sciences   \n",
       "3            3              GH Research   \n",
       "4            4                 MindMed    \n",
       "5            5                  B More    \n",
       "6            6               Apex Labs    \n",
       "7            7  Perception Neuroscience   \n",
       "8            8              GH Research   \n",
       "9            9              GH Research   \n",
       "10          10             Nova Mentis    \n",
       "11          11         Beckley Psytech    \n",
       "12          12                 MindMed    \n",
       "13          13                 MAPS PBC   \n",
       "14          14                 MAPS PBC   \n",
       "15          15         Usona Institute    \n",
       "16          16        Tryp Therapeutics   \n",
       "17          17        Compass Pathways    \n",
       "18          18        Compass Pathways    \n",
       "19          19        Braxia Scientific   \n",
       "\n",
       "                                    Study explanation  \\\n",
       "0   MAPS has completed conducting two Phase 3 tria...   \n",
       "1   COMP360 is a psilocybin formulation currently ...   \n",
       "2   Awakn is set to evaluate ketamine-assisted psy...   \n",
       "3   GH001 is an inhaled formulation of 5-MeO-DMT, ...   \n",
       "4   MM-120 is a formulation of LSD being evaluated...   \n",
       "5   SYNP-101 is a synthetic form of psilocybin bei...   \n",
       "6   APEX-52 is a low dose psilocybin formulation b...   \n",
       "7   PCN-101 is arketamine (or R-ketamine), an isom...   \n",
       "8   GH001 is an inhaled formulation of 5-MeO-DMT, ...   \n",
       "9   GH001 is an inhaled formulation of 5-MeO-DMT, ...   \n",
       "10  NM-1001 is a low dose psilocybin formulation s...   \n",
       "11  BPL-003 is an intranasal formulation of synthe...   \n",
       "12  MM-110, also known as 18-MC or zolunicant, is ...   \n",
       "13  MAPS is evaluating MDMA-assisted group therapy...   \n",
       "14  MAPS is evaluating MDMA-assisted psychotherapy...   \n",
       "15  The Usona Institute is currently evaluating ps...   \n",
       "16  TRP-8802 is an orally-delivered synthetic psil...   \n",
       "17  COMP360 is a psilocybin formulation currently ...   \n",
       "18  COMP360 is a psilocybin formulation currently ...   \n",
       "19  Braxia is evaluating psilocybin-assisted thera...   \n",
       "\n",
       "                                          Study title      Phase  \\\n",
       "0      Post-traumatic stress disorder (PTSD)  |  MDMA    Phase 3   \n",
       "1   Treatment-resistant depression (TRD)  |  COMP3...    Phase 3   \n",
       "2             Alcohol use disorder (AUD)  |  Ketamine    Phase 3   \n",
       "3   Treatment-resistant depression (TRD)| GH001 (5...   Phase 2b   \n",
       "4   Generalized Anxiety Disorder (GAD)  | MM-120 (...   Phase 2b   \n",
       "5   Alcohol Use Disorder (AUD)  |  SYNP-101 (Psilo...   Phase 2b   \n",
       "6   Post-traumatic stress disorder (PTSD)| APEX-25...   Phase 2b   \n",
       "7   Treatment-resistant depression (TRD)|  PCN-101...    Phase 2   \n",
       "8   Bipolar Disorder II (BDII)  |  GH001 (5-MeO-DM...    Phase 2   \n",
       "9   Postpartum Depression (PPD)  |  GH001 (5-MeO-D...    Phase 2   \n",
       "10      Fragile X Syndrome  |  NM-1001 (Psilocybin)     Phase 2a   \n",
       "11  Treatment-resistant depression (TRD)|  BPL-003...    Phase 2   \n",
       "12              Opioid Withdrawal  | MM-110 (18-MC)     Phase 2a   \n",
       "13     Post-traumatic stress disorder (PTSD)|  MDMA      Phase 2   \n",
       "14  Anorexia nervosa & Binge eating disorder |  MD...    Phase 2   \n",
       "15   Major Depressive Disorder (MDD)  |  Psilocybin      Phase 2   \n",
       "16           Fibromyalgia  |  TRP-8802 (Psilocybin)     Phase 2a   \n",
       "17        Anorexia Nervosa  |  COMP360 (Psilocybin)      Phase 2   \n",
       "18  Post-traumatic stress disorder (PTSD)|  COMP36...    Phase 2   \n",
       "19  Treatment-resistant depression (TRD)|  Psilocy...    Phase 2   \n",
       "\n",
       "                                 health issue  \\\n",
       "0     Post-traumatic stress disorder (PTSD)     \n",
       "1      Treatment-resistant depression (TRD)     \n",
       "2                Alcohol use disorder (AUD)     \n",
       "3        Treatment-resistant depression (TRD)   \n",
       "4        Generalized Anxiety Disorder (GAD)     \n",
       "5                Alcohol Use Disorder (AUD)     \n",
       "6       Post-traumatic stress disorder (PTSD)   \n",
       "7        Treatment-resistant depression (TRD)   \n",
       "8                Bipolar Disorder II (BDII)     \n",
       "9               Postpartum Depression (PPD)     \n",
       "10                       Fragile X Syndrome     \n",
       "11       Treatment-resistant depression (TRD)   \n",
       "12                        Opioid Withdrawal     \n",
       "13      Post-traumatic stress disorder (PTSD)   \n",
       "14  Anorexia nervosa & Binge eating disorder    \n",
       "15          Major Depressive Disorder (MDD)     \n",
       "16                             Fibromyalgia     \n",
       "17                         Anorexia Nervosa     \n",
       "18      Post-traumatic stress disorder (PTSD)   \n",
       "19       Treatment-resistant depression (TRD)   \n",
       "\n",
       "                        Lead substance  \n",
       "0                                 MDMA  \n",
       "1                 COMP360 (Psilocybin)  \n",
       "2                             Ketamine  \n",
       "3                  GH001 (5-MeO-DMT)    \n",
       "4                       MM-120 (LSD)    \n",
       "5              SYNP-101 (Psilocybin)    \n",
       "6               APEX-25 (Psilocybin)    \n",
       "7    PCN-101 (R-ketamine)   (Complete)  \n",
       "8                  GH001 (5-MeO-DMT)    \n",
       "9                  GH001 (5-MeO-DMT)    \n",
       "10              NM-1001 (Psilocybin)    \n",
       "11               BPL-003 (5-MeO-DMT)    \n",
       "12                    MM-110 (18-MC)    \n",
       "13                              MDMA    \n",
       "14                              MDMA    \n",
       "15                        Psilocybin    \n",
       "16             TRP-8802 (Psilocybin)    \n",
       "17              COMP360 (Psilocybin)    \n",
       "18              COMP360 (Psilocybin)    \n",
       "19                        Psilocybin    "
      ]
     },
     "execution_count": 123,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ftr[:20]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 124,
   "metadata": {},
   "outputs": [],
   "source": [
    "ftr['Product Molecule substance'] = ftr['Lead substance'].str.extract(r'(\\w.*)\\s')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 125,
   "metadata": {},
   "outputs": [],
   "source": [
    "ftr['Product Molecule substance'] = ftr['Product Molecule substance'].replace(r'\\((\\w.*)\\)', '', regex=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 126,
   "metadata": {},
   "outputs": [],
   "source": [
    "ftr['lead substance substract'] = ftr['Lead substance'].str.extract(r'\\((\\w.*)\\)')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 127,
   "metadata": {},
   "outputs": [],
   "source": [
    "#ftr['Lead substance'] = ftr['Lead substance'].replace(r'\\((\\w.*)\\)', '', regex=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 128,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>Lab</th>\n",
       "      <th>Study explanation</th>\n",
       "      <th>Study title</th>\n",
       "      <th>Phase</th>\n",
       "      <th>health issue</th>\n",
       "      <th>Lead substance</th>\n",
       "      <th>Product Molecule substance</th>\n",
       "      <th>lead substance substract</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>MAPS PBC</td>\n",
       "      <td>MAPS has completed conducting two Phase 3 tria...</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)  |  MDMA</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)</td>\n",
       "      <td>MDMA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>Compass Pathways</td>\n",
       "      <td>COMP360 is a psilocybin formulation currently ...</td>\n",
       "      <td>Treatment-resistant depression (TRD)  |  COMP3...</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "      <td>COMP360 (Psilocybin)</td>\n",
       "      <td>COMP360</td>\n",
       "      <td>Psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>Awakn Life Sciences</td>\n",
       "      <td>Awakn is set to evaluate ketamine-assisted psy...</td>\n",
       "      <td>Alcohol use disorder (AUD)  |  Ketamine</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Alcohol use disorder (AUD)</td>\n",
       "      <td>Ketamine</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>GH Research</td>\n",
       "      <td>GH001 is an inhaled formulation of 5-MeO-DMT, ...</td>\n",
       "      <td>Treatment-resistant depression (TRD)| GH001 (5...</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "      <td>GH001 (5-MeO-DMT)</td>\n",
       "      <td>GH001</td>\n",
       "      <td>5-MeO-DMT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>MindMed</td>\n",
       "      <td>MM-120 is a formulation of LSD being evaluated...</td>\n",
       "      <td>Generalized Anxiety Disorder (GAD)  | MM-120 (...</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>Generalized Anxiety Disorder (GAD)</td>\n",
       "      <td>MM-120 (LSD)</td>\n",
       "      <td>MM-120</td>\n",
       "      <td>LSD</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>5</td>\n",
       "      <td>B More</td>\n",
       "      <td>SYNP-101 is a synthetic form of psilocybin bei...</td>\n",
       "      <td>Alcohol Use Disorder (AUD)  |  SYNP-101 (Psilo...</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>Alcohol Use Disorder (AUD)</td>\n",
       "      <td>SYNP-101 (Psilocybin)</td>\n",
       "      <td>SYNP-101</td>\n",
       "      <td>Psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>6</td>\n",
       "      <td>Apex Labs</td>\n",
       "      <td>APEX-52 is a low dose psilocybin formulation b...</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)| APEX-25...</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)</td>\n",
       "      <td>APEX-25 (Psilocybin)</td>\n",
       "      <td>APEX-25</td>\n",
       "      <td>Psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>7</td>\n",
       "      <td>Perception Neuroscience</td>\n",
       "      <td>PCN-101 is arketamine (or R-ketamine), an isom...</td>\n",
       "      <td>Treatment-resistant depression (TRD)|  PCN-101...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "      <td>PCN-101 (R-ketamine)   (Complete)</td>\n",
       "      <td>PCN-101</td>\n",
       "      <td>R-ketamine)   (Complete</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>8</td>\n",
       "      <td>GH Research</td>\n",
       "      <td>GH001 is an inhaled formulation of 5-MeO-DMT, ...</td>\n",
       "      <td>Bipolar Disorder II (BDII)  |  GH001 (5-MeO-DM...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Bipolar Disorder II (BDII)</td>\n",
       "      <td>GH001 (5-MeO-DMT)</td>\n",
       "      <td>GH001</td>\n",
       "      <td>5-MeO-DMT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>9</td>\n",
       "      <td>GH Research</td>\n",
       "      <td>GH001 is an inhaled formulation of 5-MeO-DMT, ...</td>\n",
       "      <td>Postpartum Depression (PPD)  |  GH001 (5-MeO-D...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Postpartum Depression (PPD)</td>\n",
       "      <td>GH001 (5-MeO-DMT)</td>\n",
       "      <td>GH001</td>\n",
       "      <td>5-MeO-DMT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>10</td>\n",
       "      <td>Nova Mentis</td>\n",
       "      <td>NM-1001 is a low dose psilocybin formulation s...</td>\n",
       "      <td>Fragile X Syndrome  |  NM-1001 (Psilocybin)</td>\n",
       "      <td>Phase 2a</td>\n",
       "      <td>Fragile X Syndrome</td>\n",
       "      <td>NM-1001 (Psilocybin)</td>\n",
       "      <td>NM-1001</td>\n",
       "      <td>Psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>11</td>\n",
       "      <td>Beckley Psytech</td>\n",
       "      <td>BPL-003 is an intranasal formulation of synthe...</td>\n",
       "      <td>Treatment-resistant depression (TRD)|  BPL-003...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "      <td>BPL-003 (5-MeO-DMT)</td>\n",
       "      <td>BPL-003</td>\n",
       "      <td>5-MeO-DMT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>12</td>\n",
       "      <td>MindMed</td>\n",
       "      <td>MM-110, also known as 18-MC or zolunicant, is ...</td>\n",
       "      <td>Opioid Withdrawal  | MM-110 (18-MC)</td>\n",
       "      <td>Phase 2a</td>\n",
       "      <td>Opioid Withdrawal</td>\n",
       "      <td>MM-110 (18-MC)</td>\n",
       "      <td>MM-110</td>\n",
       "      <td>18-MC</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>13</td>\n",
       "      <td>MAPS PBC</td>\n",
       "      <td>MAPS is evaluating MDMA-assisted group therapy...</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)|  MDMA</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)</td>\n",
       "      <td>MDMA</td>\n",
       "      <td>MDMA</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>14</td>\n",
       "      <td>MAPS PBC</td>\n",
       "      <td>MAPS is evaluating MDMA-assisted psychotherapy...</td>\n",
       "      <td>Anorexia nervosa &amp; Binge eating disorder |  MD...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Anorexia nervosa &amp; Binge eating disorder</td>\n",
       "      <td>MDMA</td>\n",
       "      <td>MDMA</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>15</td>\n",
       "      <td>Usona Institute</td>\n",
       "      <td>The Usona Institute is currently evaluating ps...</td>\n",
       "      <td>Major Depressive Disorder (MDD)  |  Psilocybin</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Major Depressive Disorder (MDD)</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>16</td>\n",
       "      <td>Tryp Therapeutics</td>\n",
       "      <td>TRP-8802 is an orally-delivered synthetic psil...</td>\n",
       "      <td>Fibromyalgia  |  TRP-8802 (Psilocybin)</td>\n",
       "      <td>Phase 2a</td>\n",
       "      <td>Fibromyalgia</td>\n",
       "      <td>TRP-8802 (Psilocybin)</td>\n",
       "      <td>TRP-8802</td>\n",
       "      <td>Psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>17</td>\n",
       "      <td>Compass Pathways</td>\n",
       "      <td>COMP360 is a psilocybin formulation currently ...</td>\n",
       "      <td>Anorexia Nervosa  |  COMP360 (Psilocybin)</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Anorexia Nervosa</td>\n",
       "      <td>COMP360 (Psilocybin)</td>\n",
       "      <td>COMP360</td>\n",
       "      <td>Psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>18</td>\n",
       "      <td>Compass Pathways</td>\n",
       "      <td>COMP360 is a psilocybin formulation currently ...</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)|  COMP36...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)</td>\n",
       "      <td>COMP360 (Psilocybin)</td>\n",
       "      <td>COMP360</td>\n",
       "      <td>Psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>19</td>\n",
       "      <td>Braxia Scientific</td>\n",
       "      <td>Braxia is evaluating psilocybin-assisted thera...</td>\n",
       "      <td>Treatment-resistant depression (TRD)|  Psilocy...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>20</td>\n",
       "      <td>Janssen</td>\n",
       "      <td>SPRAVATO is an intranasal esketamine formulati...</td>\n",
       "      <td>Major Depressive Disorder (MDD)  | Spravato (E...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Major Depressive Disorder (MDD)</td>\n",
       "      <td>Spravato (Esketamine)</td>\n",
       "      <td>Spravato</td>\n",
       "      <td>Esketamine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>21</td>\n",
       "      <td>Seelos Therapeutics</td>\n",
       "      <td>SLS-002 is an intranasal racemic ketamine prod...</td>\n",
       "      <td>Acute Suicidal Ideation and Behaviour  (ASIB) ...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Acute Suicidal Ideation and Behaviour  (ASIB)</td>\n",
       "      <td>SLS-002 (Ketamine)</td>\n",
       "      <td>SLS-002</td>\n",
       "      <td>Ketamine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>22</td>\n",
       "      <td>MindMed</td>\n",
       "      <td>As part of a deal with University Hospital Bas...</td>\n",
       "      <td>Cluster Headaches  |  LSD</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Cluster Headaches</td>\n",
       "      <td>LSD</td>\n",
       "      <td>LSD</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>23</td>\n",
       "      <td>Incannex</td>\n",
       "      <td>In partnership with Monash University, Incanne...</td>\n",
       "      <td>Generalized Anxiety Disorder (GAD)  |  Psilocy...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Generalized Anxiety Disorder (GAD)</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>24</td>\n",
       "      <td>Clexio Biosciences</td>\n",
       "      <td>CLE-100 is a formulation of oral esketamine cu...</td>\n",
       "      <td>Major Depressive Disorder (MDD)  |  CLE-100 (E...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Major Depressive Disorder (MDD)</td>\n",
       "      <td>CLE-100 (Esketamine)</td>\n",
       "      <td>CLE-100</td>\n",
       "      <td>Esketamine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>25</td>\n",
       "      <td>Clairvoyant</td>\n",
       "      <td>Clairvoyant is evaluating psilocybin-assisted ...</td>\n",
       "      <td>Alcohol Use Disorder (AUD) |  Psilocybin</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Alcohol Use Disorder (AUD)</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    Unnamed: 0                      Lab  \\\n",
       "0            0                 MAPS PBC   \n",
       "1            1        Compass Pathways    \n",
       "2            2      Awakn Life Sciences   \n",
       "3            3              GH Research   \n",
       "4            4                 MindMed    \n",
       "5            5                  B More    \n",
       "6            6               Apex Labs    \n",
       "7            7  Perception Neuroscience   \n",
       "8            8              GH Research   \n",
       "9            9              GH Research   \n",
       "10          10             Nova Mentis    \n",
       "11          11         Beckley Psytech    \n",
       "12          12                 MindMed    \n",
       "13          13                 MAPS PBC   \n",
       "14          14                 MAPS PBC   \n",
       "15          15         Usona Institute    \n",
       "16          16        Tryp Therapeutics   \n",
       "17          17        Compass Pathways    \n",
       "18          18        Compass Pathways    \n",
       "19          19        Braxia Scientific   \n",
       "20          20                 Janssen    \n",
       "21          21      Seelos Therapeutics   \n",
       "22          22                 MindMed    \n",
       "23          23                 Incannex   \n",
       "24          24       Clexio Biosciences   \n",
       "25          25              Clairvoyant   \n",
       "\n",
       "                                    Study explanation  \\\n",
       "0   MAPS has completed conducting two Phase 3 tria...   \n",
       "1   COMP360 is a psilocybin formulation currently ...   \n",
       "2   Awakn is set to evaluate ketamine-assisted psy...   \n",
       "3   GH001 is an inhaled formulation of 5-MeO-DMT, ...   \n",
       "4   MM-120 is a formulation of LSD being evaluated...   \n",
       "5   SYNP-101 is a synthetic form of psilocybin bei...   \n",
       "6   APEX-52 is a low dose psilocybin formulation b...   \n",
       "7   PCN-101 is arketamine (or R-ketamine), an isom...   \n",
       "8   GH001 is an inhaled formulation of 5-MeO-DMT, ...   \n",
       "9   GH001 is an inhaled formulation of 5-MeO-DMT, ...   \n",
       "10  NM-1001 is a low dose psilocybin formulation s...   \n",
       "11  BPL-003 is an intranasal formulation of synthe...   \n",
       "12  MM-110, also known as 18-MC or zolunicant, is ...   \n",
       "13  MAPS is evaluating MDMA-assisted group therapy...   \n",
       "14  MAPS is evaluating MDMA-assisted psychotherapy...   \n",
       "15  The Usona Institute is currently evaluating ps...   \n",
       "16  TRP-8802 is an orally-delivered synthetic psil...   \n",
       "17  COMP360 is a psilocybin formulation currently ...   \n",
       "18  COMP360 is a psilocybin formulation currently ...   \n",
       "19  Braxia is evaluating psilocybin-assisted thera...   \n",
       "20  SPRAVATO is an intranasal esketamine formulati...   \n",
       "21  SLS-002 is an intranasal racemic ketamine prod...   \n",
       "22  As part of a deal with University Hospital Bas...   \n",
       "23  In partnership with Monash University, Incanne...   \n",
       "24  CLE-100 is a formulation of oral esketamine cu...   \n",
       "25  Clairvoyant is evaluating psilocybin-assisted ...   \n",
       "\n",
       "                                          Study title      Phase  \\\n",
       "0      Post-traumatic stress disorder (PTSD)  |  MDMA    Phase 3   \n",
       "1   Treatment-resistant depression (TRD)  |  COMP3...    Phase 3   \n",
       "2             Alcohol use disorder (AUD)  |  Ketamine    Phase 3   \n",
       "3   Treatment-resistant depression (TRD)| GH001 (5...   Phase 2b   \n",
       "4   Generalized Anxiety Disorder (GAD)  | MM-120 (...   Phase 2b   \n",
       "5   Alcohol Use Disorder (AUD)  |  SYNP-101 (Psilo...   Phase 2b   \n",
       "6   Post-traumatic stress disorder (PTSD)| APEX-25...   Phase 2b   \n",
       "7   Treatment-resistant depression (TRD)|  PCN-101...    Phase 2   \n",
       "8   Bipolar Disorder II (BDII)  |  GH001 (5-MeO-DM...    Phase 2   \n",
       "9   Postpartum Depression (PPD)  |  GH001 (5-MeO-D...    Phase 2   \n",
       "10      Fragile X Syndrome  |  NM-1001 (Psilocybin)     Phase 2a   \n",
       "11  Treatment-resistant depression (TRD)|  BPL-003...    Phase 2   \n",
       "12              Opioid Withdrawal  | MM-110 (18-MC)     Phase 2a   \n",
       "13     Post-traumatic stress disorder (PTSD)|  MDMA      Phase 2   \n",
       "14  Anorexia nervosa & Binge eating disorder |  MD...    Phase 2   \n",
       "15   Major Depressive Disorder (MDD)  |  Psilocybin      Phase 2   \n",
       "16           Fibromyalgia  |  TRP-8802 (Psilocybin)     Phase 2a   \n",
       "17        Anorexia Nervosa  |  COMP360 (Psilocybin)      Phase 2   \n",
       "18  Post-traumatic stress disorder (PTSD)|  COMP36...    Phase 2   \n",
       "19  Treatment-resistant depression (TRD)|  Psilocy...    Phase 2   \n",
       "20  Major Depressive Disorder (MDD)  | Spravato (E...    Phase 2   \n",
       "21  Acute Suicidal Ideation and Behaviour  (ASIB) ...    Phase 2   \n",
       "22                         Cluster Headaches  |  LSD     Phase 2   \n",
       "23  Generalized Anxiety Disorder (GAD)  |  Psilocy...    Phase 2   \n",
       "24  Major Depressive Disorder (MDD)  |  CLE-100 (E...    Phase 2   \n",
       "25         Alcohol Use Disorder (AUD) |  Psilocybin      Phase 2   \n",
       "\n",
       "                                       health issue  \\\n",
       "0           Post-traumatic stress disorder (PTSD)     \n",
       "1            Treatment-resistant depression (TRD)     \n",
       "2                      Alcohol use disorder (AUD)     \n",
       "3              Treatment-resistant depression (TRD)   \n",
       "4              Generalized Anxiety Disorder (GAD)     \n",
       "5                      Alcohol Use Disorder (AUD)     \n",
       "6             Post-traumatic stress disorder (PTSD)   \n",
       "7              Treatment-resistant depression (TRD)   \n",
       "8                      Bipolar Disorder II (BDII)     \n",
       "9                     Postpartum Depression (PPD)     \n",
       "10                             Fragile X Syndrome     \n",
       "11             Treatment-resistant depression (TRD)   \n",
       "12                              Opioid Withdrawal     \n",
       "13            Post-traumatic stress disorder (PTSD)   \n",
       "14        Anorexia nervosa & Binge eating disorder    \n",
       "15                Major Depressive Disorder (MDD)     \n",
       "16                                   Fibromyalgia     \n",
       "17                               Anorexia Nervosa     \n",
       "18            Post-traumatic stress disorder (PTSD)   \n",
       "19             Treatment-resistant depression (TRD)   \n",
       "20                Major Depressive Disorder (MDD)     \n",
       "21  Acute Suicidal Ideation and Behaviour  (ASIB)     \n",
       "22                              Cluster Headaches     \n",
       "23             Generalized Anxiety Disorder (GAD)     \n",
       "24                Major Depressive Disorder (MDD)     \n",
       "25                      Alcohol Use Disorder (AUD)    \n",
       "\n",
       "                        Lead substance Product Molecule substance  \\\n",
       "0                                 MDMA                        NaN   \n",
       "1                 COMP360 (Psilocybin)                    COMP360   \n",
       "2                             Ketamine                        NaN   \n",
       "3                  GH001 (5-MeO-DMT)                      GH001     \n",
       "4                       MM-120 (LSD)                     MM-120     \n",
       "5              SYNP-101 (Psilocybin)                   SYNP-101     \n",
       "6               APEX-25 (Psilocybin)                    APEX-25     \n",
       "7    PCN-101 (R-ketamine)   (Complete)                 PCN-101      \n",
       "8                  GH001 (5-MeO-DMT)                      GH001     \n",
       "9                  GH001 (5-MeO-DMT)                      GH001     \n",
       "10              NM-1001 (Psilocybin)                    NM-1001     \n",
       "11               BPL-003 (5-MeO-DMT)                    BPL-003     \n",
       "12                    MM-110 (18-MC)                     MM-110     \n",
       "13                              MDMA                        MDMA    \n",
       "14                              MDMA                        MDMA    \n",
       "15                        Psilocybin                  Psilocybin    \n",
       "16             TRP-8802 (Psilocybin)                   TRP-8802     \n",
       "17              COMP360 (Psilocybin)                    COMP360     \n",
       "18              COMP360 (Psilocybin)                    COMP360     \n",
       "19                        Psilocybin                  Psilocybin    \n",
       "20             Spravato (Esketamine)                   Spravato     \n",
       "21                SLS-002 (Ketamine)                    SLS-002     \n",
       "22                                LSD                         LSD   \n",
       "23                        Psilocybin                  Psilocybin    \n",
       "24              CLE-100 (Esketamine)                    CLE-100     \n",
       "25                        Psilocybin                  Psilocybin    \n",
       "\n",
       "   lead substance substract  \n",
       "0                       NaN  \n",
       "1                Psilocybin  \n",
       "2                       NaN  \n",
       "3                 5-MeO-DMT  \n",
       "4                       LSD  \n",
       "5                Psilocybin  \n",
       "6                Psilocybin  \n",
       "7   R-ketamine)   (Complete  \n",
       "8                 5-MeO-DMT  \n",
       "9                 5-MeO-DMT  \n",
       "10               Psilocybin  \n",
       "11                5-MeO-DMT  \n",
       "12                    18-MC  \n",
       "13                      NaN  \n",
       "14                      NaN  \n",
       "15                      NaN  \n",
       "16               Psilocybin  \n",
       "17               Psilocybin  \n",
       "18               Psilocybin  \n",
       "19                      NaN  \n",
       "20               Esketamine  \n",
       "21                 Ketamine  \n",
       "22                      NaN  \n",
       "23                      NaN  \n",
       "24               Esketamine  \n",
       "25                      NaN  "
      ]
     },
     "execution_count": 128,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ftr[:26]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 129,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['Unnamed: 0', 'Lab', 'Study explanation', 'Study title', 'Phase',\n",
       "       'health issue', 'Lead substance', 'Product Molecule substance',\n",
       "       'lead substance substract'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 129,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ftr.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 130,
   "metadata": {},
   "outputs": [],
   "source": [
    "ftr = ftr.reindex(columns=['Unnamed: 0', 'Lab', 'Study explanation', 'Study title', 'Phase',\n",
    "       'health issue', 'Product Molecule substance', 'Lead substance',\n",
    "       'lead substance substract'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 131,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>Lab</th>\n",
       "      <th>Study explanation</th>\n",
       "      <th>Study title</th>\n",
       "      <th>Phase</th>\n",
       "      <th>health issue</th>\n",
       "      <th>Product Molecule substance</th>\n",
       "      <th>Lead substance</th>\n",
       "      <th>lead substance substract</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>MAPS PBC</td>\n",
       "      <td>MAPS has completed conducting two Phase 3 tria...</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)  |  MDMA</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>MDMA</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>Compass Pathways</td>\n",
       "      <td>COMP360 is a psilocybin formulation currently ...</td>\n",
       "      <td>Treatment-resistant depression (TRD)  |  COMP3...</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "      <td>COMP360</td>\n",
       "      <td>COMP360 (Psilocybin)</td>\n",
       "      <td>Psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>Awakn Life Sciences</td>\n",
       "      <td>Awakn is set to evaluate ketamine-assisted psy...</td>\n",
       "      <td>Alcohol use disorder (AUD)  |  Ketamine</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Alcohol use disorder (AUD)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Ketamine</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>GH Research</td>\n",
       "      <td>GH001 is an inhaled formulation of 5-MeO-DMT, ...</td>\n",
       "      <td>Treatment-resistant depression (TRD)| GH001 (5...</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "      <td>GH001</td>\n",
       "      <td>GH001 (5-MeO-DMT)</td>\n",
       "      <td>5-MeO-DMT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>MindMed</td>\n",
       "      <td>MM-120 is a formulation of LSD being evaluated...</td>\n",
       "      <td>Generalized Anxiety Disorder (GAD)  | MM-120 (...</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>Generalized Anxiety Disorder (GAD)</td>\n",
       "      <td>MM-120</td>\n",
       "      <td>MM-120 (LSD)</td>\n",
       "      <td>LSD</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>83</td>\n",
       "      <td>PSYLO</td>\n",
       "      <td>Psylo is currently in the discovery stages of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>84</td>\n",
       "      <td>Mindstate Design</td>\n",
       "      <td>MSD-101, MSD-102, MSD-103, MSD-104, MSD-105 Di...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>85</td>\n",
       "      <td>Lusaris Therapeutics</td>\n",
       "      <td>Lusaris is developing a portfolio of new compo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>86</td>\n",
       "      <td>Beckley Psytech</td>\n",
       "      <td>NCE discovery program.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>87</td>\n",
       "      <td>Onsero</td>\n",
       "      <td>Onsero is developing a portfolio of unknown 5-...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>88 rows Ã— 9 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    Unnamed: 0                    Lab  \\\n",
       "0            0               MAPS PBC   \n",
       "1            1      Compass Pathways    \n",
       "2            2    Awakn Life Sciences   \n",
       "3            3            GH Research   \n",
       "4            4               MindMed    \n",
       "..         ...                    ...   \n",
       "83          83                 PSYLO    \n",
       "84          84       Mindstate Design   \n",
       "85          85  Lusaris Therapeutics    \n",
       "86          86       Beckley Psytech    \n",
       "87          87                Onsero    \n",
       "\n",
       "                                    Study explanation  \\\n",
       "0   MAPS has completed conducting two Phase 3 tria...   \n",
       "1   COMP360 is a psilocybin formulation currently ...   \n",
       "2   Awakn is set to evaluate ketamine-assisted psy...   \n",
       "3   GH001 is an inhaled formulation of 5-MeO-DMT, ...   \n",
       "4   MM-120 is a formulation of LSD being evaluated...   \n",
       "..                                                ...   \n",
       "83  Psylo is currently in the discovery stages of ...   \n",
       "84  MSD-101, MSD-102, MSD-103, MSD-104, MSD-105 Di...   \n",
       "85  Lusaris is developing a portfolio of new compo...   \n",
       "86                             NCE discovery program.   \n",
       "87  Onsero is developing a portfolio of unknown 5-...   \n",
       "\n",
       "                                          Study title      Phase  \\\n",
       "0      Post-traumatic stress disorder (PTSD)  |  MDMA    Phase 3   \n",
       "1   Treatment-resistant depression (TRD)  |  COMP3...    Phase 3   \n",
       "2             Alcohol use disorder (AUD)  |  Ketamine    Phase 3   \n",
       "3   Treatment-resistant depression (TRD)| GH001 (5...   Phase 2b   \n",
       "4   Generalized Anxiety Disorder (GAD)  | MM-120 (...   Phase 2b   \n",
       "..                                                ...        ...   \n",
       "83                                                NaN        NaN   \n",
       "84                                                NaN        NaN   \n",
       "85                                                NaN        NaN   \n",
       "86                                                NaN        NaN   \n",
       "87                                                NaN        NaN   \n",
       "\n",
       "                               health issue Product Molecule substance  \\\n",
       "0   Post-traumatic stress disorder (PTSD)                          NaN   \n",
       "1    Treatment-resistant depression (TRD)                      COMP360   \n",
       "2              Alcohol use disorder (AUD)                          NaN   \n",
       "3      Treatment-resistant depression (TRD)                    GH001     \n",
       "4      Generalized Anxiety Disorder (GAD)                     MM-120     \n",
       "..                                      ...                        ...   \n",
       "83                                      NaN                        NaN   \n",
       "84                                      NaN                        NaN   \n",
       "85                                      NaN                        NaN   \n",
       "86                                      NaN                        NaN   \n",
       "87                                      NaN                        NaN   \n",
       "\n",
       "           Lead substance lead substance substract  \n",
       "0                    MDMA                      NaN  \n",
       "1    COMP360 (Psilocybin)               Psilocybin  \n",
       "2                Ketamine                      NaN  \n",
       "3     GH001 (5-MeO-DMT)                  5-MeO-DMT  \n",
       "4          MM-120 (LSD)                        LSD  \n",
       "..                    ...                      ...  \n",
       "83                    NaN                      NaN  \n",
       "84                    NaN                      NaN  \n",
       "85                    NaN                      NaN  \n",
       "86                    NaN                      NaN  \n",
       "87                    NaN                      NaN  \n",
       "\n",
       "[88 rows x 9 columns]"
      ]
     },
     "execution_count": 131,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ftr"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 132,
   "metadata": {},
   "outputs": [],
   "source": [
    "#ftr['lead substance substract'] = ftr['lead substance substract'].fillna(method='ffill')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 133,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>Lab</th>\n",
       "      <th>Study explanation</th>\n",
       "      <th>Study title</th>\n",
       "      <th>Phase</th>\n",
       "      <th>health issue</th>\n",
       "      <th>Product Molecule substance</th>\n",
       "      <th>Lead substance</th>\n",
       "      <th>lead substance substract</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>MAPS PBC</td>\n",
       "      <td>MAPS has completed conducting two Phase 3 tria...</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)  |  MDMA</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>MDMA</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>Compass Pathways</td>\n",
       "      <td>COMP360 is a psilocybin formulation currently ...</td>\n",
       "      <td>Treatment-resistant depression (TRD)  |  COMP3...</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "      <td>COMP360</td>\n",
       "      <td>COMP360 (Psilocybin)</td>\n",
       "      <td>Psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>Awakn Life Sciences</td>\n",
       "      <td>Awakn is set to evaluate ketamine-assisted psy...</td>\n",
       "      <td>Alcohol use disorder (AUD)  |  Ketamine</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Alcohol use disorder (AUD)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Ketamine</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>GH Research</td>\n",
       "      <td>GH001 is an inhaled formulation of 5-MeO-DMT, ...</td>\n",
       "      <td>Treatment-resistant depression (TRD)| GH001 (5...</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "      <td>GH001</td>\n",
       "      <td>GH001 (5-MeO-DMT)</td>\n",
       "      <td>5-MeO-DMT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>MindMed</td>\n",
       "      <td>MM-120 is a formulation of LSD being evaluated...</td>\n",
       "      <td>Generalized Anxiety Disorder (GAD)  | MM-120 (...</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>Generalized Anxiety Disorder (GAD)</td>\n",
       "      <td>MM-120</td>\n",
       "      <td>MM-120 (LSD)</td>\n",
       "      <td>LSD</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>5</td>\n",
       "      <td>B More</td>\n",
       "      <td>SYNP-101 is a synthetic form of psilocybin bei...</td>\n",
       "      <td>Alcohol Use Disorder (AUD)  |  SYNP-101 (Psilo...</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>Alcohol Use Disorder (AUD)</td>\n",
       "      <td>SYNP-101</td>\n",
       "      <td>SYNP-101 (Psilocybin)</td>\n",
       "      <td>Psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>6</td>\n",
       "      <td>Apex Labs</td>\n",
       "      <td>APEX-52 is a low dose psilocybin formulation b...</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)| APEX-25...</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)</td>\n",
       "      <td>APEX-25</td>\n",
       "      <td>APEX-25 (Psilocybin)</td>\n",
       "      <td>Psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>7</td>\n",
       "      <td>Perception Neuroscience</td>\n",
       "      <td>PCN-101 is arketamine (or R-ketamine), an isom...</td>\n",
       "      <td>Treatment-resistant depression (TRD)|  PCN-101...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "      <td>PCN-101</td>\n",
       "      <td>PCN-101 (R-ketamine)   (Complete)</td>\n",
       "      <td>R-ketamine)   (Complete</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>8</td>\n",
       "      <td>GH Research</td>\n",
       "      <td>GH001 is an inhaled formulation of 5-MeO-DMT, ...</td>\n",
       "      <td>Bipolar Disorder II (BDII)  |  GH001 (5-MeO-DM...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Bipolar Disorder II (BDII)</td>\n",
       "      <td>GH001</td>\n",
       "      <td>GH001 (5-MeO-DMT)</td>\n",
       "      <td>5-MeO-DMT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>9</td>\n",
       "      <td>GH Research</td>\n",
       "      <td>GH001 is an inhaled formulation of 5-MeO-DMT, ...</td>\n",
       "      <td>Postpartum Depression (PPD)  |  GH001 (5-MeO-D...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Postpartum Depression (PPD)</td>\n",
       "      <td>GH001</td>\n",
       "      <td>GH001 (5-MeO-DMT)</td>\n",
       "      <td>5-MeO-DMT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>10</td>\n",
       "      <td>Nova Mentis</td>\n",
       "      <td>NM-1001 is a low dose psilocybin formulation s...</td>\n",
       "      <td>Fragile X Syndrome  |  NM-1001 (Psilocybin)</td>\n",
       "      <td>Phase 2a</td>\n",
       "      <td>Fragile X Syndrome</td>\n",
       "      <td>NM-1001</td>\n",
       "      <td>NM-1001 (Psilocybin)</td>\n",
       "      <td>Psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>11</td>\n",
       "      <td>Beckley Psytech</td>\n",
       "      <td>BPL-003 is an intranasal formulation of synthe...</td>\n",
       "      <td>Treatment-resistant depression (TRD)|  BPL-003...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "      <td>BPL-003</td>\n",
       "      <td>BPL-003 (5-MeO-DMT)</td>\n",
       "      <td>5-MeO-DMT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>12</td>\n",
       "      <td>MindMed</td>\n",
       "      <td>MM-110, also known as 18-MC or zolunicant, is ...</td>\n",
       "      <td>Opioid Withdrawal  | MM-110 (18-MC)</td>\n",
       "      <td>Phase 2a</td>\n",
       "      <td>Opioid Withdrawal</td>\n",
       "      <td>MM-110</td>\n",
       "      <td>MM-110 (18-MC)</td>\n",
       "      <td>18-MC</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>13</td>\n",
       "      <td>MAPS PBC</td>\n",
       "      <td>MAPS is evaluating MDMA-assisted group therapy...</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)|  MDMA</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)</td>\n",
       "      <td>MDMA</td>\n",
       "      <td>MDMA</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>14</td>\n",
       "      <td>MAPS PBC</td>\n",
       "      <td>MAPS is evaluating MDMA-assisted psychotherapy...</td>\n",
       "      <td>Anorexia nervosa &amp; Binge eating disorder |  MD...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Anorexia nervosa &amp; Binge eating disorder</td>\n",
       "      <td>MDMA</td>\n",
       "      <td>MDMA</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>15</td>\n",
       "      <td>Usona Institute</td>\n",
       "      <td>The Usona Institute is currently evaluating ps...</td>\n",
       "      <td>Major Depressive Disorder (MDD)  |  Psilocybin</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Major Depressive Disorder (MDD)</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>16</td>\n",
       "      <td>Tryp Therapeutics</td>\n",
       "      <td>TRP-8802 is an orally-delivered synthetic psil...</td>\n",
       "      <td>Fibromyalgia  |  TRP-8802 (Psilocybin)</td>\n",
       "      <td>Phase 2a</td>\n",
       "      <td>Fibromyalgia</td>\n",
       "      <td>TRP-8802</td>\n",
       "      <td>TRP-8802 (Psilocybin)</td>\n",
       "      <td>Psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>17</td>\n",
       "      <td>Compass Pathways</td>\n",
       "      <td>COMP360 is a psilocybin formulation currently ...</td>\n",
       "      <td>Anorexia Nervosa  |  COMP360 (Psilocybin)</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Anorexia Nervosa</td>\n",
       "      <td>COMP360</td>\n",
       "      <td>COMP360 (Psilocybin)</td>\n",
       "      <td>Psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>18</td>\n",
       "      <td>Compass Pathways</td>\n",
       "      <td>COMP360 is a psilocybin formulation currently ...</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)|  COMP36...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)</td>\n",
       "      <td>COMP360</td>\n",
       "      <td>COMP360 (Psilocybin)</td>\n",
       "      <td>Psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>19</td>\n",
       "      <td>Braxia Scientific</td>\n",
       "      <td>Braxia is evaluating psilocybin-assisted thera...</td>\n",
       "      <td>Treatment-resistant depression (TRD)|  Psilocy...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>20</td>\n",
       "      <td>Janssen</td>\n",
       "      <td>SPRAVATO is an intranasal esketamine formulati...</td>\n",
       "      <td>Major Depressive Disorder (MDD)  | Spravato (E...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Major Depressive Disorder (MDD)</td>\n",
       "      <td>Spravato</td>\n",
       "      <td>Spravato (Esketamine)</td>\n",
       "      <td>Esketamine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>21</td>\n",
       "      <td>Seelos Therapeutics</td>\n",
       "      <td>SLS-002 is an intranasal racemic ketamine prod...</td>\n",
       "      <td>Acute Suicidal Ideation and Behaviour  (ASIB) ...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Acute Suicidal Ideation and Behaviour  (ASIB)</td>\n",
       "      <td>SLS-002</td>\n",
       "      <td>SLS-002 (Ketamine)</td>\n",
       "      <td>Ketamine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>22</td>\n",
       "      <td>MindMed</td>\n",
       "      <td>As part of a deal with University Hospital Bas...</td>\n",
       "      <td>Cluster Headaches  |  LSD</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Cluster Headaches</td>\n",
       "      <td>LSD</td>\n",
       "      <td>LSD</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>23</td>\n",
       "      <td>Incannex</td>\n",
       "      <td>In partnership with Monash University, Incanne...</td>\n",
       "      <td>Generalized Anxiety Disorder (GAD)  |  Psilocy...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Generalized Anxiety Disorder (GAD)</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>24</td>\n",
       "      <td>Clexio Biosciences</td>\n",
       "      <td>CLE-100 is a formulation of oral esketamine cu...</td>\n",
       "      <td>Major Depressive Disorder (MDD)  |  CLE-100 (E...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Major Depressive Disorder (MDD)</td>\n",
       "      <td>CLE-100</td>\n",
       "      <td>CLE-100 (Esketamine)</td>\n",
       "      <td>Esketamine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>25</td>\n",
       "      <td>Clairvoyant</td>\n",
       "      <td>Clairvoyant is evaluating psilocybin-assisted ...</td>\n",
       "      <td>Alcohol Use Disorder (AUD) |  Psilocybin</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Alcohol Use Disorder (AUD)</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>26</td>\n",
       "      <td>Ceruvia Lifesciences</td>\n",
       "      <td>SYNP-101 is a synthetic form of psilocybin bei...</td>\n",
       "      <td>Obsessive Compulsive Disorder (OCD) |  SYNP-10...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Obsessive Compulsive Disorder (OCD)</td>\n",
       "      <td>SYNP-101</td>\n",
       "      <td>SYNP-101 (Psilocybin)</td>\n",
       "      <td>Psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>27</td>\n",
       "      <td>Psyence</td>\n",
       "      <td>Psyence is set to evaluate psilocybin-assisted...</td>\n",
       "      <td>Adjustment Disorder  |  Psilocybin</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Adjustment Disorder</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>28</td>\n",
       "      <td>Beckley Psytech</td>\n",
       "      <td>BPL-003 is an intranasal formulation of synthe...</td>\n",
       "      <td>Alcohol Use Disorder (AUD)  |  BPL-003 (5-MeO-...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Alcohol Use Disorder (AUD)</td>\n",
       "      <td>BPL-003</td>\n",
       "      <td>BPL-003 (5-MeO-DMT)</td>\n",
       "      <td>5-MeO-DMT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>29</td>\n",
       "      <td>SmallPharma</td>\n",
       "      <td>Top-line results from Small Pharma's Phase IIa...</td>\n",
       "      <td>Major Depressive Disorder (MDD) |  SPL026 (DMT...</td>\n",
       "      <td>Phase 2a</td>\n",
       "      <td>Major Depressive Disorder (MDD)</td>\n",
       "      <td>SPL026</td>\n",
       "      <td>SPL026 (DMT)   (Completed)</td>\n",
       "      <td>DMT)   (Completed</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>30</td>\n",
       "      <td>MindMed</td>\n",
       "      <td>MM-120 is a formulation of LSD being evaluated...</td>\n",
       "      <td>Attention Deficit Disorder (ADHD)  |  MM120 (L...</td>\n",
       "      <td>Phase 2a</td>\n",
       "      <td>Attention Deficit Disorder (ADHD)</td>\n",
       "      <td>MM120</td>\n",
       "      <td>MM120 (LSD)</td>\n",
       "      <td>LSD</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>31</td>\n",
       "      <td>Cybin</td>\n",
       "      <td>CYB003 is an orally dissolving tablet formulat...</td>\n",
       "      <td>Major Depressive Disorder (MDD)  |  CYB003 (De...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Major Depressive Disorder (MDD)</td>\n",
       "      <td>CYB003</td>\n",
       "      <td>CYB003 (Deuterated Psilocybin Analog)  /2</td>\n",
       "      <td>Deuterated Psilocybin Analog</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>32</td>\n",
       "      <td>DemeRx</td>\n",
       "      <td>DMX-1002 is an ibogaine formulation set to be ...</td>\n",
       "      <td>Opiate Withdrawal Syndrome  |  DMX-1002 (Iboga...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Opiate Withdrawal Syndrome</td>\n",
       "      <td>DMX-1002</td>\n",
       "      <td>DMX-1002 (Ibogaine)  /2</td>\n",
       "      <td>Ibogaine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>33</td>\n",
       "      <td>Beckley Psytech</td>\n",
       "      <td>ELE-001 is an intravenous (IV) formulation of ...</td>\n",
       "      <td>Major Depressive Disorder (MDD)  |  ELE-101 (P...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Major Depressive Disorder (MDD)</td>\n",
       "      <td>ELE-101</td>\n",
       "      <td>ELE-101 (Psilocin)  /2</td>\n",
       "      <td>Psilocin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>34</td>\n",
       "      <td>Algernon Pharmaceuticals</td>\n",
       "      <td>AP-188 is a sub-hallucinogenic, IV DMT formula...</td>\n",
       "      <td>Ischemic Stroke  |  AP-188 (DMT)</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Ischemic Stroke</td>\n",
       "      <td>AP-188</td>\n",
       "      <td>AP-188 (DMT)</td>\n",
       "      <td>DMT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>35</td>\n",
       "      <td>biomind labs</td>\n",
       "      <td>BMND01 is a liquid inhaled formulation of DMT ...</td>\n",
       "      <td>Healthy Volunteers |  BMND01 (DMT)</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Healthy Volunteers</td>\n",
       "      <td>BMND01</td>\n",
       "      <td>BMND01 (DMT)</td>\n",
       "      <td>DMT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>36</td>\n",
       "      <td>Optimi Health</td>\n",
       "      <td>MELOCIN is a naturally derived Psilocybe extra...</td>\n",
       "      <td>Healthy Volunteers  |  Psilocybin</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Healthy Volunteers</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>37</td>\n",
       "      <td>MindMed</td>\n",
       "      <td>MM-402 is R(-)-MDMA, an isomer of MDMA, as a p...</td>\n",
       "      <td>Autism Spectrum Disorder (ASD)  |  MM-402 (R(-...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Autism Spectrum Disorder (ASD)</td>\n",
       "      <td>MM-402</td>\n",
       "      <td>MM-402 (R(-)-MDMA)</td>\n",
       "      <td>R(-)-MDMA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>38</td>\n",
       "      <td>MindMed</td>\n",
       "      <td>MindMed is evaluating mescaline in a Phase I t...</td>\n",
       "      <td>Healthy Volunteers  |  Mescaline</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Healthy Volunteers</td>\n",
       "      <td>Mescaline</td>\n",
       "      <td>Mescaline</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>39</td>\n",
       "      <td>Reunion</td>\n",
       "      <td>RE104 is isoprocin glutarate, a prodrug of 4-H...</td>\n",
       "      <td>Healthy Volunteers  |  RE104 (4-HO-DiPT; Isopr...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Healthy Volunteers</td>\n",
       "      <td>RE104</td>\n",
       "      <td>RE104 (4-HO-DiPT; Isoprocin Glutarate)</td>\n",
       "      <td>4-HO-DiPT; Isoprocin Glutarate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>40</td>\n",
       "      <td>Ceruvia Lifesciences</td>\n",
       "      <td>NYPRG-101 is a non-hallucinogenic LSD analog, ...</td>\n",
       "      <td>Cluster Headaches |  NYPRG-101 (BOL-148)</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Cluster Headaches</td>\n",
       "      <td>NYPRG-101</td>\n",
       "      <td>NYPRG-101 (BOL-148)</td>\n",
       "      <td>BOL-148</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>41</td>\n",
       "      <td>GH Research</td>\n",
       "      <td>GH002 is an injectable formulation of 5-MeO-DM...</td>\n",
       "      <td>Healthy Volunteers  |  GH002 (5-MeO-DMT)</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Healthy Volunteers</td>\n",
       "      <td>GH002</td>\n",
       "      <td>GH002 (5-MeO-DMT)</td>\n",
       "      <td>5-MeO-DMT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>42</td>\n",
       "      <td>MindSet</td>\n",
       "      <td>MSP-1014 is a deuterated prodrug of psilocybin...</td>\n",
       "      <td>Major Depressive Disorder (MDD)  |  MSP-1014 (...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Major Depressive Disorder (MDD)</td>\n",
       "      <td>MSP-1014</td>\n",
       "      <td>MSP-1014 (Deuterated Psilocybin Prodrug)</td>\n",
       "      <td>Deuterated Psilocybin Prodrug</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>43</td>\n",
       "      <td>EmpathBio</td>\n",
       "      <td>EmpathBio is developing EMP-01, an MDMA-deriva...</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)|  EMP-01...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)</td>\n",
       "      <td>EMP-01</td>\n",
       "      <td>EMP-01 (MDMA Derivative)</td>\n",
       "      <td>MDMA Derivative</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>44</td>\n",
       "      <td>SmallPharma</td>\n",
       "      <td>SPL026 is a formulation of DMT being developed...</td>\n",
       "      <td>Major Depressive Disorder (MDD)  |  SPL029 (DM...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Major Depressive Disorder (MDD)</td>\n",
       "      <td>SPL029</td>\n",
       "      <td>SPL029 (DMT)</td>\n",
       "      <td>DMT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>45</td>\n",
       "      <td>SmallPharma</td>\n",
       "      <td>SPL028 is a formulation of an unknown deuterat...</td>\n",
       "      <td>Healthy Volunteers  |  SPL028 (Deuterated DMT)</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Healthy Volunteers</td>\n",
       "      <td>SPL028</td>\n",
       "      <td>SPL028 (Deuterated DMT)</td>\n",
       "      <td>Deuterated DMT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>46</td>\n",
       "      <td>Viridia Life Sciences</td>\n",
       "      <td>VLS-01 is a formulation of DMT intended for po...</td>\n",
       "      <td>Treatment-resistant depression (TRD)|  VLS-01 ...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "      <td>VLS-01</td>\n",
       "      <td>VLS-01 (DMT)</td>\n",
       "      <td>DMT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>47</td>\n",
       "      <td>Bright Minds Biosciences</td>\n",
       "      <td>BMB-101 is an unknown 5-HT2C agonist being eva...</td>\n",
       "      <td>Healthy Volunteers  |  BMB-101 (5-HT2C Agonist)</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Healthy Volunteers</td>\n",
       "      <td>BMB-101</td>\n",
       "      <td>BMB-101 (5-HT2C Agonist)</td>\n",
       "      <td>5-HT2C Agonist</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>48</td>\n",
       "      <td>Diamond Therapeutics</td>\n",
       "      <td>Diamond Therapeutics' lead programme is the de...</td>\n",
       "      <td>Anxiety Disorders  |  Psilocybin</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Anxiety Disorders</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>49</td>\n",
       "      <td>Ceruvia Lifesciences</td>\n",
       "      <td>NYPRG-101 is a non-hallucinogenic LSD analog, ...</td>\n",
       "      <td>Migraines  |  NYPRG-101 (BOL-148)</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Migraines</td>\n",
       "      <td>NYPRG-101</td>\n",
       "      <td>NYPRG-101 (BOL-148)</td>\n",
       "      <td>BOL-148</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    Unnamed: 0                       Lab  \\\n",
       "0            0                  MAPS PBC   \n",
       "1            1         Compass Pathways    \n",
       "2            2       Awakn Life Sciences   \n",
       "3            3               GH Research   \n",
       "4            4                  MindMed    \n",
       "5            5                   B More    \n",
       "6            6                Apex Labs    \n",
       "7            7   Perception Neuroscience   \n",
       "8            8               GH Research   \n",
       "9            9               GH Research   \n",
       "10          10              Nova Mentis    \n",
       "11          11          Beckley Psytech    \n",
       "12          12                  MindMed    \n",
       "13          13                  MAPS PBC   \n",
       "14          14                  MAPS PBC   \n",
       "15          15          Usona Institute    \n",
       "16          16         Tryp Therapeutics   \n",
       "17          17         Compass Pathways    \n",
       "18          18         Compass Pathways    \n",
       "19          19         Braxia Scientific   \n",
       "20          20                  Janssen    \n",
       "21          21       Seelos Therapeutics   \n",
       "22          22                  MindMed    \n",
       "23          23                  Incannex   \n",
       "24          24        Clexio Biosciences   \n",
       "25          25               Clairvoyant   \n",
       "26          26      Ceruvia Lifesciences   \n",
       "27          27                   Psyence   \n",
       "28          28          Beckley Psytech    \n",
       "29          29               SmallPharma   \n",
       "30          30                  MindMed    \n",
       "31          31                     Cybin   \n",
       "32          32                   DemeRx    \n",
       "33          33          Beckley Psytech    \n",
       "34          34  Algernon Pharmaceuticals   \n",
       "35          35              biomind labs   \n",
       "36          36             Optimi Health   \n",
       "37          37                  MindMed    \n",
       "38          38                  MindMed    \n",
       "39          39                  Reunion    \n",
       "40          40      Ceruvia Lifesciences   \n",
       "41          41               GH Research   \n",
       "42          42                   MindSet   \n",
       "43          43                EmpathBio    \n",
       "44          44               SmallPharma   \n",
       "45          45               SmallPharma   \n",
       "46          46     Viridia Life Sciences   \n",
       "47          47  Bright Minds Biosciences   \n",
       "48          48      Diamond Therapeutics   \n",
       "49          49      Ceruvia Lifesciences   \n",
       "\n",
       "                                    Study explanation  \\\n",
       "0   MAPS has completed conducting two Phase 3 tria...   \n",
       "1   COMP360 is a psilocybin formulation currently ...   \n",
       "2   Awakn is set to evaluate ketamine-assisted psy...   \n",
       "3   GH001 is an inhaled formulation of 5-MeO-DMT, ...   \n",
       "4   MM-120 is a formulation of LSD being evaluated...   \n",
       "5   SYNP-101 is a synthetic form of psilocybin bei...   \n",
       "6   APEX-52 is a low dose psilocybin formulation b...   \n",
       "7   PCN-101 is arketamine (or R-ketamine), an isom...   \n",
       "8   GH001 is an inhaled formulation of 5-MeO-DMT, ...   \n",
       "9   GH001 is an inhaled formulation of 5-MeO-DMT, ...   \n",
       "10  NM-1001 is a low dose psilocybin formulation s...   \n",
       "11  BPL-003 is an intranasal formulation of synthe...   \n",
       "12  MM-110, also known as 18-MC or zolunicant, is ...   \n",
       "13  MAPS is evaluating MDMA-assisted group therapy...   \n",
       "14  MAPS is evaluating MDMA-assisted psychotherapy...   \n",
       "15  The Usona Institute is currently evaluating ps...   \n",
       "16  TRP-8802 is an orally-delivered synthetic psil...   \n",
       "17  COMP360 is a psilocybin formulation currently ...   \n",
       "18  COMP360 is a psilocybin formulation currently ...   \n",
       "19  Braxia is evaluating psilocybin-assisted thera...   \n",
       "20  SPRAVATO is an intranasal esketamine formulati...   \n",
       "21  SLS-002 is an intranasal racemic ketamine prod...   \n",
       "22  As part of a deal with University Hospital Bas...   \n",
       "23  In partnership with Monash University, Incanne...   \n",
       "24  CLE-100 is a formulation of oral esketamine cu...   \n",
       "25  Clairvoyant is evaluating psilocybin-assisted ...   \n",
       "26  SYNP-101 is a synthetic form of psilocybin bei...   \n",
       "27  Psyence is set to evaluate psilocybin-assisted...   \n",
       "28  BPL-003 is an intranasal formulation of synthe...   \n",
       "29  Top-line results from Small Pharma's Phase IIa...   \n",
       "30  MM-120 is a formulation of LSD being evaluated...   \n",
       "31  CYB003 is an orally dissolving tablet formulat...   \n",
       "32  DMX-1002 is an ibogaine formulation set to be ...   \n",
       "33  ELE-001 is an intravenous (IV) formulation of ...   \n",
       "34  AP-188 is a sub-hallucinogenic, IV DMT formula...   \n",
       "35  BMND01 is a liquid inhaled formulation of DMT ...   \n",
       "36  MELOCIN is a naturally derived Psilocybe extra...   \n",
       "37  MM-402 is R(-)-MDMA, an isomer of MDMA, as a p...   \n",
       "38  MindMed is evaluating mescaline in a Phase I t...   \n",
       "39  RE104 is isoprocin glutarate, a prodrug of 4-H...   \n",
       "40  NYPRG-101 is a non-hallucinogenic LSD analog, ...   \n",
       "41  GH002 is an injectable formulation of 5-MeO-DM...   \n",
       "42  MSP-1014 is a deuterated prodrug of psilocybin...   \n",
       "43  EmpathBio is developing EMP-01, an MDMA-deriva...   \n",
       "44  SPL026 is a formulation of DMT being developed...   \n",
       "45  SPL028 is a formulation of an unknown deuterat...   \n",
       "46  VLS-01 is a formulation of DMT intended for po...   \n",
       "47  BMB-101 is an unknown 5-HT2C agonist being eva...   \n",
       "48  Diamond Therapeutics' lead programme is the de...   \n",
       "49  NYPRG-101 is a non-hallucinogenic LSD analog, ...   \n",
       "\n",
       "                                          Study title      Phase  \\\n",
       "0      Post-traumatic stress disorder (PTSD)  |  MDMA    Phase 3   \n",
       "1   Treatment-resistant depression (TRD)  |  COMP3...    Phase 3   \n",
       "2             Alcohol use disorder (AUD)  |  Ketamine    Phase 3   \n",
       "3   Treatment-resistant depression (TRD)| GH001 (5...   Phase 2b   \n",
       "4   Generalized Anxiety Disorder (GAD)  | MM-120 (...   Phase 2b   \n",
       "5   Alcohol Use Disorder (AUD)  |  SYNP-101 (Psilo...   Phase 2b   \n",
       "6   Post-traumatic stress disorder (PTSD)| APEX-25...   Phase 2b   \n",
       "7   Treatment-resistant depression (TRD)|  PCN-101...    Phase 2   \n",
       "8   Bipolar Disorder II (BDII)  |  GH001 (5-MeO-DM...    Phase 2   \n",
       "9   Postpartum Depression (PPD)  |  GH001 (5-MeO-D...    Phase 2   \n",
       "10      Fragile X Syndrome  |  NM-1001 (Psilocybin)     Phase 2a   \n",
       "11  Treatment-resistant depression (TRD)|  BPL-003...    Phase 2   \n",
       "12              Opioid Withdrawal  | MM-110 (18-MC)     Phase 2a   \n",
       "13     Post-traumatic stress disorder (PTSD)|  MDMA      Phase 2   \n",
       "14  Anorexia nervosa & Binge eating disorder |  MD...    Phase 2   \n",
       "15   Major Depressive Disorder (MDD)  |  Psilocybin      Phase 2   \n",
       "16           Fibromyalgia  |  TRP-8802 (Psilocybin)     Phase 2a   \n",
       "17        Anorexia Nervosa  |  COMP360 (Psilocybin)      Phase 2   \n",
       "18  Post-traumatic stress disorder (PTSD)|  COMP36...    Phase 2   \n",
       "19  Treatment-resistant depression (TRD)|  Psilocy...    Phase 2   \n",
       "20  Major Depressive Disorder (MDD)  | Spravato (E...    Phase 2   \n",
       "21  Acute Suicidal Ideation and Behaviour  (ASIB) ...    Phase 2   \n",
       "22                         Cluster Headaches  |  LSD     Phase 2   \n",
       "23  Generalized Anxiety Disorder (GAD)  |  Psilocy...    Phase 2   \n",
       "24  Major Depressive Disorder (MDD)  |  CLE-100 (E...    Phase 2   \n",
       "25         Alcohol Use Disorder (AUD) |  Psilocybin      Phase 2   \n",
       "26  Obsessive Compulsive Disorder (OCD) |  SYNP-10...    Phase 2   \n",
       "27               Adjustment Disorder  |  Psilocybin      Phase 2   \n",
       "28  Alcohol Use Disorder (AUD)  |  BPL-003 (5-MeO-...    Phase 2   \n",
       "29  Major Depressive Disorder (MDD) |  SPL026 (DMT...   Phase 2a   \n",
       "30  Attention Deficit Disorder (ADHD)  |  MM120 (L...   Phase 2a   \n",
       "31  Major Depressive Disorder (MDD)  |  CYB003 (De...    Phase 1   \n",
       "32  Opiate Withdrawal Syndrome  |  DMX-1002 (Iboga...    Phase 1   \n",
       "33  Major Depressive Disorder (MDD)  |  ELE-101 (P...    Phase 1   \n",
       "34                 Ischemic Stroke  |  AP-188 (DMT)      Phase 1   \n",
       "35               Healthy Volunteers |  BMND01 (DMT)      Phase 1   \n",
       "36                Healthy Volunteers  |  Psilocybin      Phase 1   \n",
       "37  Autism Spectrum Disorder (ASD)  |  MM-402 (R(-...    Phase 1   \n",
       "38                 Healthy Volunteers  |  Mescaline      Phase 1   \n",
       "39  Healthy Volunteers  |  RE104 (4-HO-DiPT; Isopr...    Phase 1   \n",
       "40         Cluster Headaches |  NYPRG-101 (BOL-148)      Phase 1   \n",
       "41         Healthy Volunteers  |  GH002 (5-MeO-DMT)      Phase 1   \n",
       "42  Major Depressive Disorder (MDD)  |  MSP-1014 (...    Phase 1   \n",
       "43  Post-traumatic stress disorder (PTSD)|  EMP-01...    Phase 1   \n",
       "44  Major Depressive Disorder (MDD)  |  SPL029 (DM...    Phase 1   \n",
       "45   Healthy Volunteers  |  SPL028 (Deuterated DMT)      Phase 1   \n",
       "46  Treatment-resistant depression (TRD)|  VLS-01 ...    Phase 1   \n",
       "47  Healthy Volunteers  |  BMB-101 (5-HT2C Agonist)      Phase 1   \n",
       "48                 Anxiety Disorders  |  Psilocybin      Phase 1   \n",
       "49                Migraines  |  NYPRG-101 (BOL-148)      Phase 1   \n",
       "\n",
       "                                       health issue  \\\n",
       "0           Post-traumatic stress disorder (PTSD)     \n",
       "1            Treatment-resistant depression (TRD)     \n",
       "2                      Alcohol use disorder (AUD)     \n",
       "3              Treatment-resistant depression (TRD)   \n",
       "4              Generalized Anxiety Disorder (GAD)     \n",
       "5                      Alcohol Use Disorder (AUD)     \n",
       "6             Post-traumatic stress disorder (PTSD)   \n",
       "7              Treatment-resistant depression (TRD)   \n",
       "8                      Bipolar Disorder II (BDII)     \n",
       "9                     Postpartum Depression (PPD)     \n",
       "10                             Fragile X Syndrome     \n",
       "11             Treatment-resistant depression (TRD)   \n",
       "12                              Opioid Withdrawal     \n",
       "13            Post-traumatic stress disorder (PTSD)   \n",
       "14        Anorexia nervosa & Binge eating disorder    \n",
       "15                Major Depressive Disorder (MDD)     \n",
       "16                                   Fibromyalgia     \n",
       "17                               Anorexia Nervosa     \n",
       "18            Post-traumatic stress disorder (PTSD)   \n",
       "19             Treatment-resistant depression (TRD)   \n",
       "20                Major Depressive Disorder (MDD)     \n",
       "21  Acute Suicidal Ideation and Behaviour  (ASIB)     \n",
       "22                              Cluster Headaches     \n",
       "23             Generalized Anxiety Disorder (GAD)     \n",
       "24                Major Depressive Disorder (MDD)     \n",
       "25                      Alcohol Use Disorder (AUD)    \n",
       "26             Obsessive Compulsive Disorder (OCD)    \n",
       "27                            Adjustment Disorder     \n",
       "28                     Alcohol Use Disorder (AUD)     \n",
       "29                 Major Depressive Disorder (MDD)    \n",
       "30              Attention Deficit Disorder (ADHD)     \n",
       "31                Major Depressive Disorder (MDD)     \n",
       "32                     Opiate Withdrawal Syndrome     \n",
       "33                Major Depressive Disorder (MDD)     \n",
       "34                                Ischemic Stroke     \n",
       "35                              Healthy Volunteers    \n",
       "36                             Healthy Volunteers     \n",
       "37                 Autism Spectrum Disorder (ASD)     \n",
       "38                             Healthy Volunteers     \n",
       "39                             Healthy Volunteers     \n",
       "40                               Cluster Headaches    \n",
       "41                             Healthy Volunteers     \n",
       "42                Major Depressive Disorder (MDD)     \n",
       "43            Post-traumatic stress disorder (PTSD)   \n",
       "44                Major Depressive Disorder (MDD)     \n",
       "45                             Healthy Volunteers     \n",
       "46             Treatment-resistant depression (TRD)   \n",
       "47                             Healthy Volunteers     \n",
       "48                              Anxiety Disorders     \n",
       "49                                      Migraines     \n",
       "\n",
       "   Product Molecule substance                               Lead substance  \\\n",
       "0                         NaN                                         MDMA   \n",
       "1                     COMP360                         COMP360 (Psilocybin)   \n",
       "2                         NaN                                     Ketamine   \n",
       "3                     GH001                            GH001 (5-MeO-DMT)     \n",
       "4                    MM-120                                 MM-120 (LSD)     \n",
       "5                  SYNP-101                        SYNP-101 (Psilocybin)     \n",
       "6                   APEX-25                         APEX-25 (Psilocybin)     \n",
       "7                  PCN-101               PCN-101 (R-ketamine)   (Complete)   \n",
       "8                     GH001                            GH001 (5-MeO-DMT)     \n",
       "9                     GH001                            GH001 (5-MeO-DMT)     \n",
       "10                  NM-1001                         NM-1001 (Psilocybin)     \n",
       "11                  BPL-003                          BPL-003 (5-MeO-DMT)     \n",
       "12                   MM-110                               MM-110 (18-MC)     \n",
       "13                      MDMA                                        MDMA     \n",
       "14                      MDMA                                        MDMA     \n",
       "15                Psilocybin                                  Psilocybin     \n",
       "16                 TRP-8802                        TRP-8802 (Psilocybin)     \n",
       "17                  COMP360                         COMP360 (Psilocybin)     \n",
       "18                  COMP360                         COMP360 (Psilocybin)     \n",
       "19                Psilocybin                                  Psilocybin     \n",
       "20                 Spravato                        Spravato (Esketamine)     \n",
       "21                  SLS-002                           SLS-002 (Ketamine)     \n",
       "22                        LSD                                         LSD    \n",
       "23                Psilocybin                                  Psilocybin     \n",
       "24                  CLE-100                         CLE-100 (Esketamine)     \n",
       "25                Psilocybin                                  Psilocybin     \n",
       "26                 SYNP-101                        SYNP-101 (Psilocybin)     \n",
       "27                Psilocybin                                  Psilocybin     \n",
       "28                  BPL-003                          BPL-003 (5-MeO-DMT)     \n",
       "29                  SPL026                      SPL026 (DMT)   (Completed)   \n",
       "30                    MM120                                  MM120 (LSD)     \n",
       "31                   CYB003      CYB003 (Deuterated Psilocybin Analog)  /2   \n",
       "32                 DMX-1002                        DMX-1002 (Ibogaine)  /2   \n",
       "33                  ELE-101                         ELE-101 (Psilocin)  /2   \n",
       "34                   AP-188                                 AP-188 (DMT)     \n",
       "35                   BMND01                                 BMND01 (DMT)     \n",
       "36                Psilocybin                                  Psilocybin     \n",
       "37                    MM-402                           MM-402 (R(-)-MDMA)    \n",
       "38                 Mescaline                                   Mescaline     \n",
       "39                    RE104       RE104 (4-HO-DiPT; Isoprocin Glutarate)     \n",
       "40                NYPRG-101                          NYPRG-101 (BOL-148)     \n",
       "41                    GH002                            GH002 (5-MeO-DMT)     \n",
       "42                 MSP-1014     MSP-1014 (Deuterated Psilocybin Prodrug)     \n",
       "43                   EMP-01                     EMP-01 (MDMA Derivative)     \n",
       "44                   SPL029                                 SPL029 (DMT)     \n",
       "45                   SPL028                      SPL028 (Deuterated DMT)     \n",
       "46                   VLS-01                                 VLS-01 (DMT)     \n",
       "47                  BMB-101                     BMB-101 (5-HT2C Agonist)     \n",
       "48                Psilocybin                                  Psilocybin     \n",
       "49                NYPRG-101                          NYPRG-101 (BOL-148)     \n",
       "\n",
       "          lead substance substract  \n",
       "0                              NaN  \n",
       "1                       Psilocybin  \n",
       "2                              NaN  \n",
       "3                        5-MeO-DMT  \n",
       "4                              LSD  \n",
       "5                       Psilocybin  \n",
       "6                       Psilocybin  \n",
       "7          R-ketamine)   (Complete  \n",
       "8                        5-MeO-DMT  \n",
       "9                        5-MeO-DMT  \n",
       "10                      Psilocybin  \n",
       "11                       5-MeO-DMT  \n",
       "12                           18-MC  \n",
       "13                             NaN  \n",
       "14                             NaN  \n",
       "15                             NaN  \n",
       "16                      Psilocybin  \n",
       "17                      Psilocybin  \n",
       "18                      Psilocybin  \n",
       "19                             NaN  \n",
       "20                      Esketamine  \n",
       "21                        Ketamine  \n",
       "22                             NaN  \n",
       "23                             NaN  \n",
       "24                      Esketamine  \n",
       "25                             NaN  \n",
       "26                      Psilocybin  \n",
       "27                             NaN  \n",
       "28                       5-MeO-DMT  \n",
       "29               DMT)   (Completed  \n",
       "30                             LSD  \n",
       "31    Deuterated Psilocybin Analog  \n",
       "32                        Ibogaine  \n",
       "33                        Psilocin  \n",
       "34                             DMT  \n",
       "35                             DMT  \n",
       "36                             NaN  \n",
       "37                       R(-)-MDMA  \n",
       "38                             NaN  \n",
       "39  4-HO-DiPT; Isoprocin Glutarate  \n",
       "40                         BOL-148  \n",
       "41                       5-MeO-DMT  \n",
       "42   Deuterated Psilocybin Prodrug  \n",
       "43                 MDMA Derivative  \n",
       "44                             DMT  \n",
       "45                  Deuterated DMT  \n",
       "46                             DMT  \n",
       "47                  5-HT2C Agonist  \n",
       "48                             NaN  \n",
       "49                         BOL-148  "
      ]
     },
     "execution_count": 133,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ftr[:50]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 134,
   "metadata": {},
   "outputs": [],
   "source": [
    "ftr['lead substance substract'] = ftr['lead substance substract'].fillna(value=ftr['Lead substance'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 135,
   "metadata": {},
   "outputs": [],
   "source": [
    "ftr_01 = ftr.iloc[:50,:]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 136,
   "metadata": {},
   "outputs": [],
   "source": [
    "ftr_trials = pd.read_csv('./final_tracking_excel_preclinical.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 137,
   "metadata": {},
   "outputs": [],
   "source": [
    "ftr_trials_01 =ftr_trials.iloc[:30,:]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 138,
   "metadata": {},
   "outputs": [],
   "source": [
    "ftr_atom = pd.concat([ftr_01,ftr_trials_01], axis=0, ignore_index='True')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 139,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>Lab</th>\n",
       "      <th>Study explanation</th>\n",
       "      <th>Study title</th>\n",
       "      <th>Phase</th>\n",
       "      <th>health issue</th>\n",
       "      <th>Product Molecule substance</th>\n",
       "      <th>Lead substance</th>\n",
       "      <th>lead substance substract</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0.0</td>\n",
       "      <td>MAPS PBC</td>\n",
       "      <td>MAPS has completed conducting two Phase 3 tria...</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)  |  MDMA</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>MDMA</td>\n",
       "      <td>MDMA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1.0</td>\n",
       "      <td>Compass Pathways</td>\n",
       "      <td>COMP360 is a psilocybin formulation currently ...</td>\n",
       "      <td>Treatment-resistant depression (TRD)  |  COMP3...</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "      <td>COMP360</td>\n",
       "      <td>COMP360 (Psilocybin)</td>\n",
       "      <td>Psilocybin</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Unnamed: 0                Lab  \\\n",
       "0         0.0           MAPS PBC   \n",
       "1         1.0  Compass Pathways    \n",
       "\n",
       "                                   Study explanation  \\\n",
       "0  MAPS has completed conducting two Phase 3 tria...   \n",
       "1  COMP360 is a psilocybin formulation currently ...   \n",
       "\n",
       "                                         Study title     Phase  \\\n",
       "0     Post-traumatic stress disorder (PTSD)  |  MDMA   Phase 3   \n",
       "1  Treatment-resistant depression (TRD)  |  COMP3...   Phase 3   \n",
       "\n",
       "                              health issue Product Molecule substance  \\\n",
       "0  Post-traumatic stress disorder (PTSD)                          NaN   \n",
       "1   Treatment-resistant depression (TRD)                      COMP360   \n",
       "\n",
       "          Lead substance lead substance substract  \n",
       "0                   MDMA                     MDMA  \n",
       "1   COMP360 (Psilocybin)               Psilocybin  "
      ]
     },
     "execution_count": 139,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ftr_atom[:2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 140,
   "metadata": {},
   "outputs": [],
   "source": [
    "ftr_atom = ftr_atom.drop(['Unnamed: 0', 'Lead substance'], axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 141,
   "metadata": {},
   "outputs": [],
   "source": [
    "#ftr_atom.to_csv('./ftr_atom.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 142,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['Lab', 'Study explanation', 'Study title', 'Phase', 'health issue',\n",
       "       'Product Molecule substance', 'lead substance substract'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 142,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ftr_atom.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 143,
   "metadata": {},
   "outputs": [],
   "source": [
    "ftr_atom['lead substance substract'] = ftr_atom['lead substance substract'].astype(str)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 144,
   "metadata": {},
   "outputs": [],
   "source": [
    "ftr_atom['lead substance substract'] = ftr_atom['lead substance substract'].str.lstrip()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 145,
   "metadata": {},
   "outputs": [],
   "source": [
    "ftr_atom['lead substance substract'] = ftr_atom['lead substance substract'].str.lower()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 146,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Lab</th>\n",
       "      <th>Study explanation</th>\n",
       "      <th>Study title</th>\n",
       "      <th>Phase</th>\n",
       "      <th>health issue</th>\n",
       "      <th>Product Molecule substance</th>\n",
       "      <th>lead substance substract</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>MAPS PBC</td>\n",
       "      <td>MAPS has completed conducting two Phase 3 tria...</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)  |  MDMA</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>mdma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Compass Pathways</td>\n",
       "      <td>COMP360 is a psilocybin formulation currently ...</td>\n",
       "      <td>Treatment-resistant depression (TRD)  |  COMP3...</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "      <td>COMP360</td>\n",
       "      <td>psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Awakn Life Sciences</td>\n",
       "      <td>Awakn is set to evaluate ketamine-assisted psy...</td>\n",
       "      <td>Alcohol use disorder (AUD)  |  Ketamine</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Alcohol use disorder (AUD)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ketamine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>GH Research</td>\n",
       "      <td>GH001 is an inhaled formulation of 5-MeO-DMT, ...</td>\n",
       "      <td>Treatment-resistant depression (TRD)| GH001 (5...</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "      <td>GH001</td>\n",
       "      <td>5-meo-dmt</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>MindMed</td>\n",
       "      <td>MM-120 is a formulation of LSD being evaluated...</td>\n",
       "      <td>Generalized Anxiety Disorder (GAD)  | MM-120 (...</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>Generalized Anxiety Disorder (GAD)</td>\n",
       "      <td>MM-120</td>\n",
       "      <td>lsd</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>B More</td>\n",
       "      <td>SYNP-101 is a synthetic form of psilocybin bei...</td>\n",
       "      <td>Alcohol Use Disorder (AUD)  |  SYNP-101 (Psilo...</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>Alcohol Use Disorder (AUD)</td>\n",
       "      <td>SYNP-101</td>\n",
       "      <td>psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Apex Labs</td>\n",
       "      <td>APEX-52 is a low dose psilocybin formulation b...</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)| APEX-25...</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)</td>\n",
       "      <td>APEX-25</td>\n",
       "      <td>psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Perception Neuroscience</td>\n",
       "      <td>PCN-101 is arketamine (or R-ketamine), an isom...</td>\n",
       "      <td>Treatment-resistant depression (TRD)|  PCN-101...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Treatment-resistant depression (TRD)</td>\n",
       "      <td>PCN-101</td>\n",
       "      <td>r-ketamine)   (complete</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>GH Research</td>\n",
       "      <td>GH001 is an inhaled formulation of 5-MeO-DMT, ...</td>\n",
       "      <td>Bipolar Disorder II (BDII)  |  GH001 (5-MeO-DM...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Bipolar Disorder II (BDII)</td>\n",
       "      <td>GH001</td>\n",
       "      <td>5-meo-dmt</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                       Lab                                  Study explanation  \\\n",
       "0                 MAPS PBC  MAPS has completed conducting two Phase 3 tria...   \n",
       "1        Compass Pathways   COMP360 is a psilocybin formulation currently ...   \n",
       "2      Awakn Life Sciences  Awakn is set to evaluate ketamine-assisted psy...   \n",
       "3              GH Research  GH001 is an inhaled formulation of 5-MeO-DMT, ...   \n",
       "4                 MindMed   MM-120 is a formulation of LSD being evaluated...   \n",
       "5                  B More   SYNP-101 is a synthetic form of psilocybin bei...   \n",
       "6               Apex Labs   APEX-52 is a low dose psilocybin formulation b...   \n",
       "7  Perception Neuroscience  PCN-101 is arketamine (or R-ketamine), an isom...   \n",
       "8              GH Research  GH001 is an inhaled formulation of 5-MeO-DMT, ...   \n",
       "\n",
       "                                         Study title      Phase  \\\n",
       "0     Post-traumatic stress disorder (PTSD)  |  MDMA    Phase 3   \n",
       "1  Treatment-resistant depression (TRD)  |  COMP3...    Phase 3   \n",
       "2            Alcohol use disorder (AUD)  |  Ketamine    Phase 3   \n",
       "3  Treatment-resistant depression (TRD)| GH001 (5...   Phase 2b   \n",
       "4  Generalized Anxiety Disorder (GAD)  | MM-120 (...   Phase 2b   \n",
       "5  Alcohol Use Disorder (AUD)  |  SYNP-101 (Psilo...   Phase 2b   \n",
       "6  Post-traumatic stress disorder (PTSD)| APEX-25...   Phase 2b   \n",
       "7  Treatment-resistant depression (TRD)|  PCN-101...    Phase 2   \n",
       "8  Bipolar Disorder II (BDII)  |  GH001 (5-MeO-DM...    Phase 2   \n",
       "\n",
       "                              health issue Product Molecule substance  \\\n",
       "0  Post-traumatic stress disorder (PTSD)                          NaN   \n",
       "1   Treatment-resistant depression (TRD)                      COMP360   \n",
       "2             Alcohol use disorder (AUD)                          NaN   \n",
       "3     Treatment-resistant depression (TRD)                    GH001     \n",
       "4     Generalized Anxiety Disorder (GAD)                     MM-120     \n",
       "5             Alcohol Use Disorder (AUD)                   SYNP-101     \n",
       "6    Post-traumatic stress disorder (PTSD)                  APEX-25     \n",
       "7     Treatment-resistant depression (TRD)                 PCN-101      \n",
       "8             Bipolar Disorder II (BDII)                      GH001     \n",
       "\n",
       "  lead substance substract  \n",
       "0                     mdma  \n",
       "1               psilocybin  \n",
       "2                 ketamine  \n",
       "3                5-meo-dmt  \n",
       "4                      lsd  \n",
       "5               psilocybin  \n",
       "6               psilocybin  \n",
       "7  r-ketamine)   (complete  \n",
       "8                5-meo-dmt  "
      ]
     },
     "execution_count": 146,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ftr_atom.head(9)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 147,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "ftr_atom['health issue']=ftr_atom['health issue'].str.replace(r'\\((\\w.*)\\)','',regex=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 148,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Lab</th>\n",
       "      <th>Study explanation</th>\n",
       "      <th>Study title</th>\n",
       "      <th>Phase</th>\n",
       "      <th>health issue</th>\n",
       "      <th>Product Molecule substance</th>\n",
       "      <th>lead substance substract</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>MAPS PBC</td>\n",
       "      <td>MAPS has completed conducting two Phase 3 tria...</td>\n",
       "      <td>Post-traumatic stress disorder (PTSD)  |  MDMA</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Post-traumatic stress disorder</td>\n",
       "      <td>NaN</td>\n",
       "      <td>mdma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Compass Pathways</td>\n",
       "      <td>COMP360 is a psilocybin formulation currently ...</td>\n",
       "      <td>Treatment-resistant depression (TRD)  |  COMP3...</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Treatment-resistant depression</td>\n",
       "      <td>COMP360</td>\n",
       "      <td>psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Awakn Life Sciences</td>\n",
       "      <td>Awakn is set to evaluate ketamine-assisted psy...</td>\n",
       "      <td>Alcohol use disorder (AUD)  |  Ketamine</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Alcohol use disorder</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ketamine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>GH Research</td>\n",
       "      <td>GH001 is an inhaled formulation of 5-MeO-DMT, ...</td>\n",
       "      <td>Treatment-resistant depression (TRD)| GH001 (5...</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>Treatment-resistant depression</td>\n",
       "      <td>GH001</td>\n",
       "      <td>5-meo-dmt</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>MindMed</td>\n",
       "      <td>MM-120 is a formulation of LSD being evaluated...</td>\n",
       "      <td>Generalized Anxiety Disorder (GAD)  | MM-120 (...</td>\n",
       "      <td>Phase 2b</td>\n",
       "      <td>Generalized Anxiety Disorder</td>\n",
       "      <td>MM-120</td>\n",
       "      <td>lsd</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75</th>\n",
       "      <td>Clearmind Medicine</td>\n",
       "      <td>CMND-100 is a synthetic form of MEAI</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Preclinical</td>\n",
       "      <td>NaN</td>\n",
       "      <td>MEAI</td>\n",
       "      <td>nan</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>76</th>\n",
       "      <td>Tryp Therapeutics</td>\n",
       "      <td>TRP-8802 is an orally-delivered synthetic psil...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Preclinical</td>\n",
       "      <td>phantom limb pain</td>\n",
       "      <td>TRP-8802</td>\n",
       "      <td>psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>77</th>\n",
       "      <td>Lusaris Therapeutics</td>\n",
       "      <td>LSR-1019 is a sublingual formulation of 5-MeO-...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Preclinical</td>\n",
       "      <td>Treatment-resistant depression</td>\n",
       "      <td>LSR-1019</td>\n",
       "      <td>dmt</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>78</th>\n",
       "      <td>Empyrean</td>\n",
       "      <td>PsiD+.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Preclinical</td>\n",
       "      <td>central nervous system disorders</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>psilocybin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>79</th>\n",
       "      <td>Mindstate Design</td>\n",
       "      <td>MSD-100.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Preclinical</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Psilocybin</td>\n",
       "      <td>psilocybin</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>80 rows Ã— 7 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                      Lab                                  Study explanation  \\\n",
       "0                MAPS PBC  MAPS has completed conducting two Phase 3 tria...   \n",
       "1       Compass Pathways   COMP360 is a psilocybin formulation currently ...   \n",
       "2     Awakn Life Sciences  Awakn is set to evaluate ketamine-assisted psy...   \n",
       "3             GH Research  GH001 is an inhaled formulation of 5-MeO-DMT, ...   \n",
       "4                MindMed   MM-120 is a formulation of LSD being evaluated...   \n",
       "..                    ...                                                ...   \n",
       "75     Clearmind Medicine               CMND-100 is a synthetic form of MEAI   \n",
       "76      Tryp Therapeutics  TRP-8802 is an orally-delivered synthetic psil...   \n",
       "77  Lusaris Therapeutics   LSR-1019 is a sublingual formulation of 5-MeO-...   \n",
       "78              Empyrean                                              PsiD+.   \n",
       "79       Mindstate Design                                           MSD-100.   \n",
       "\n",
       "                                          Study title        Phase  \\\n",
       "0      Post-traumatic stress disorder (PTSD)  |  MDMA      Phase 3   \n",
       "1   Treatment-resistant depression (TRD)  |  COMP3...      Phase 3   \n",
       "2             Alcohol use disorder (AUD)  |  Ketamine      Phase 3   \n",
       "3   Treatment-resistant depression (TRD)| GH001 (5...     Phase 2b   \n",
       "4   Generalized Anxiety Disorder (GAD)  | MM-120 (...     Phase 2b   \n",
       "..                                                ...          ...   \n",
       "75                                                NaN  Preclinical   \n",
       "76                                                NaN  Preclinical   \n",
       "77                                                NaN  Preclinical   \n",
       "78                                                NaN  Preclinical   \n",
       "79                                                NaN  Preclinical   \n",
       "\n",
       "                         health issue Product Molecule substance  \\\n",
       "0   Post-traumatic stress disorder                           NaN   \n",
       "1   Treatment-resistant depression                       COMP360   \n",
       "2             Alcohol use disorder                           NaN   \n",
       "3     Treatment-resistant depression                     GH001     \n",
       "4     Generalized Anxiety Disorder                      MM-120     \n",
       "..                                ...                        ...   \n",
       "75                                NaN                       MEAI   \n",
       "76                  phantom limb pain                   TRP-8802   \n",
       "77    Treatment-resistant depression                    LSR-1019   \n",
       "78   central nervous system disorders                 Psilocybin   \n",
       "79                                NaN                 Psilocybin   \n",
       "\n",
       "   lead substance substract  \n",
       "0                      mdma  \n",
       "1                psilocybin  \n",
       "2                  ketamine  \n",
       "3                 5-meo-dmt  \n",
       "4                       lsd  \n",
       "..                      ...  \n",
       "75                      nan  \n",
       "76               psilocybin  \n",
       "77                      dmt  \n",
       "78               psilocybin  \n",
       "79               psilocybin  \n",
       "\n",
       "[80 rows x 7 columns]"
      ]
     },
     "execution_count": 148,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ftr_atom"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 150,
   "metadata": {},
   "outputs": [],
   "source": [
    "ftr_atom.to_csv('./ftr_atom_normalize.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "\n",
       "<div id=\"altair-viz-3e1007bc9bf041bc82b6980176680084\"></div>\n",
       "<script type=\"text/javascript\">\n",
       "  var VEGA_DEBUG = (typeof VEGA_DEBUG == \"undefined\") ? {} : VEGA_DEBUG;\n",
       "  (function(spec, embedOpt){\n",
       "    let outputDiv = document.currentScript.previousElementSibling;\n",
       "    if (outputDiv.id !== \"altair-viz-3e1007bc9bf041bc82b6980176680084\") {\n",
       "      outputDiv = document.getElementById(\"altair-viz-3e1007bc9bf041bc82b6980176680084\");\n",
       "    }\n",
       "    const paths = {\n",
       "      \"vega\": \"https://cdn.jsdelivr.net/npm//vega@5?noext\",\n",
       "      \"vega-lib\": \"https://cdn.jsdelivr.net/npm//vega-lib?noext\",\n",
       "      \"vega-lite\": \"https://cdn.jsdelivr.net/npm//vega-lite@4.17.0?noext\",\n",
       "      \"vega-embed\": \"https://cdn.jsdelivr.net/npm//vega-embed@6?noext\",\n",
       "    };\n",
       "\n",
       "    function maybeLoadScript(lib, version) {\n",
       "      var key = `${lib.replace(\"-\", \"\")}_version`;\n",
       "      return (VEGA_DEBUG[key] == version) ?\n",
       "        Promise.resolve(paths[lib]) :\n",
       "        new Promise(function(resolve, reject) {\n",
       "          var s = document.createElement('script');\n",
       "          document.getElementsByTagName(\"head\")[0].appendChild(s);\n",
       "          s.async = true;\n",
       "          s.onload = () => {\n",
       "            VEGA_DEBUG[key] = version;\n",
       "            return resolve(paths[lib]);\n",
       "          };\n",
       "          s.onerror = () => reject(`Error loading script: ${paths[lib]}`);\n",
       "          s.src = paths[lib];\n",
       "        });\n",
       "    }\n",
       "\n",
       "    function showError(err) {\n",
       "      outputDiv.innerHTML = `<div class=\"error\" style=\"color:red;\">${err}</div>`;\n",
       "      throw err;\n",
       "    }\n",
       "\n",
       "    function displayChart(vegaEmbed) {\n",
       "      vegaEmbed(outputDiv, spec, embedOpt)\n",
       "        .catch(err => showError(`Javascript Error: ${err.message}<br>This usually means there's a typo in your chart specification. See the javascript console for the full traceback.`));\n",
       "    }\n",
       "\n",
       "    if(typeof define === \"function\" && define.amd) {\n",
       "      requirejs.config({paths});\n",
       "      require([\"vega-embed\"], displayChart, err => showError(`Error loading script: ${err.message}`));\n",
       "    } else {\n",
       "      maybeLoadScript(\"vega\", \"5\")\n",
       "        .then(() => maybeLoadScript(\"vega-lite\", \"4.17.0\"))\n",
       "        .then(() => maybeLoadScript(\"vega-embed\", \"6\"))\n",
       "        .catch(showError)\n",
       "        .then(() => displayChart(vegaEmbed));\n",
       "    }\n",
       "  })({\"config\": {\"view\": {\"continuousWidth\": 400, \"continuousHeight\": 300}}, \"data\": {\"name\": \"data-0a74d4a85c45ae67ffa8cef1a9126550\"}, \"mark\": \"bar\", \"encoding\": {\"x\": {\"field\": \"phase\", \"type\": \"nominal\"}, \"y\": {\"aggregate\": \"count\", \"type\": \"quantitative\"}}, \"$schema\": \"https://vega.github.io/schema/vega-lite/v4.17.0.json\", \"datasets\": {\"data-0a74d4a85c45ae67ffa8cef1a9126550\": [{\"lab\": \"MAPS PBC\", \"study explanation\": \"MAPS has completed conducting two Phase 3 trials investigating MDMA-assisted psychotherapy as a potential treatment of post-traumatic stress disorder after receiving Breakthrough Therapy Status from the FDA. The first Phase III study (MAPP1) ispublished hereand a second Phase III study (MAPP2) was announced as completed in December 2022 (NCT04077437).\", \"study title\": \"Post-traumatic stress disorder (PTSD)  |  MDMA\", \"phase\": \" Phase 3\", \"health issue\": \"Post-traumatic stress disorder   \", \"product molecule substance\": null, \"lead substance substract\": \"MDMA\"}, {\"lab\": \"Compass Pathways \", \"study explanation\": \"COMP360 is a psilocybin formulation currently being evaluated for potential use in treatment-resistant depression, after receiving Breakthrough Therapy Status from the FDA. Compass' Phase 3 program is composed of three clinical trials, two pivotal trials (known as COMP 005 and COMP 006) and one long-term follow-up, and is expected to commence by the end of 2022. More details about COMP005 can be found in the clinical trial registration link below. To learn more about the design of the Phase 3 studies, seePsychedelic Alpha Bulletin #120.\", \"study title\": \"Treatment-resistant depression (TRD)  |  COMP360 (Psilocybin)\", \"phase\": \" Phase 3\", \"health issue\": \"Treatment-resistant depression   \", \"product molecule substance\": \"COMP360\", \"lead substance substract\": \"Psilocybin\"}, {\"lab\": \"Awakn Life Sciences\", \"study explanation\": \"Awakn is set to evaluate ketamine-assisted psychotherapy in a Phase 3 trial for the treatment of alcohol use disorder. Results from the Phase 2 trial can befound here.\", \"study title\": \"Alcohol use disorder (AUD)  |  Ketamine\", \"phase\": \" Phase 3\", \"health issue\": \"Alcohol use disorder   \", \"product molecule substance\": null, \"lead substance substract\": \"Ketamine\"}, {\"lab\": \"GH Research\", \"study explanation\": \"GH001 is an inhaled formulation of 5-MeO-DMT, a short-acting psychedelic. GH001 is set to be evaluated in a Phase 2b trial for potential use in treatment-resistant depression. More details about the Phase 2b study can be found in the clinical trial registration link below. A combined Phase I/II study investigating GH001 for potential use in treatment-resistant depression was completed in 2021. The results of a Phase I study of GH001 werepublished here.\", \"study title\": \"Treatment-resistant depression (TRD)| GH001 (5-MeO-DMT)  \", \"phase\": \" Phase 2b\", \"health issue\": \"Treatment-resistant depression \", \"product molecule substance\": \"GH001  \", \"lead substance substract\": \"5-MeO-DMT\"}, {\"lab\": \"MindMed \", \"study explanation\": \"MM-120 is a formulation of LSD being evaluated in a Phase 2b study as a potential treatment for generalized anxiety disorder. As part of a deal with University Hospital Basel's Liechti Lab, MindMed acquired the rights to a completed Phase 2 trial, which waspublished here.\", \"study title\": \"Generalized Anxiety Disorder (GAD)  | MM-120 (LSD)  \", \"phase\": \" Phase 2b\", \"health issue\": \"Generalized Anxiety Disorder   \", \"product molecule substance\": \"MM-120  \", \"lead substance substract\": \"LSD\"}, {\"lab\": \"B More \", \"study explanation\": \"SYNP-101 is a synthetic form of psilocybin being developed by B.More. SYNP-101 is set to be evaluated in a Phase 2b trial as a potential treatment for alcohol use disorder. The results of an associated pilot trial can befound here.\", \"study title\": \"Alcohol Use Disorder (AUD)  |  SYNP-101 (Psilocybin)  \", \"phase\": \" Phase 2b\", \"health issue\": \"Alcohol Use Disorder   \", \"product molecule substance\": \"SYNP-101  \", \"lead substance substract\": \"Psilocybin\"}, {\"lab\": \"Apex Labs \", \"study explanation\": \"APEX-52 is a low dose psilocybin formulation being evaluated in a Phase 2b study as a potential take home treatment for depression in veterans with PTSD.\", \"study title\": \"Post-traumatic stress disorder (PTSD)| APEX-25 (Psilocybin)  \", \"phase\": \" Phase 2b\", \"health issue\": \"Post-traumatic stress disorder \", \"product molecule substance\": \"APEX-25  \", \"lead substance substract\": \"Psilocybin\"}, {\"lab\": \"Perception Neuroscience\", \"study explanation\": \"PCN-101 is arketamine (or R-ketamine), an isomer of ketamine. PCN-101 was evaluated in a Phase II trial for potential use in treatment-resistant depression. More details about the study can be found in the clinical trial registration below. Perception Neuroscience is one of atai Life Sciences' drug development programs.\", \"study title\": \"Treatment-resistant depression (TRD)|  PCN-101 (R-ketamine)   (Complete)\", \"phase\": \" Phase 2\", \"health issue\": \"Treatment-resistant depression \", \"product molecule substance\": \"PCN-101   \", \"lead substance substract\": \"R-ketamine)   (Complete\"}, {\"lab\": \"GH Research\", \"study explanation\": \"GH001 is an inhaled formulation of 5-MeO-DMT, a short-acting psychedelic. GH001 is being evaluated in a Phase 2 trial in patients with bipolar II disorder and a current major depressive episode. More details about the Phase 2 study can be found in the clinical trial registration link below.\", \"study title\": \"Bipolar Disorder II (BDII)  |  GH001 (5-MeO-DMT)  \", \"phase\": \" Phase 2\", \"health issue\": \"Bipolar Disorder II   \", \"product molecule substance\": \"GH001  \", \"lead substance substract\": \"5-MeO-DMT\"}, {\"lab\": \"GH Research\", \"study explanation\": \"GH001 is an inhaled formulation of 5-MeO-DMT, a short-acting psychedelic. GH001 is being evaluated in a Phase 2 trial in patients with postpartum depression. More details about the Phase 2 study can be found in the clinical trial registration link below.\", \"study title\": \"Postpartum Depression (PPD)  |  GH001 (5-MeO-DMT)  \", \"phase\": \" Phase 2\", \"health issue\": \"Postpartum Depression   \", \"product molecule substance\": \"GH001  \", \"lead substance substract\": \"5-MeO-DMT\"}, {\"lab\": \"Nova Mentis \", \"study explanation\": \"NM-1001 is a low dose psilocybin formulation set to be evaluated in a Phase 2a trial as a potential treatment for Fragile X Syndrome. Nova Mentis was granted orphan drug designation from the FDA and European Medicines Agency for the development of NM-1001. Results from preclinical studies on NM-1001 can befound here.\", \"study title\": \"Fragile X Syndrome  |  NM-1001 (Psilocybin)  \", \"phase\": \" Phase 2a\", \"health issue\": \"Fragile X Syndrome  \", \"product molecule substance\": \"NM-1001  \", \"lead substance substract\": \"Psilocybin\"}, {\"lab\": \"Beckley Psytech \", \"study explanation\": \"BPL-003 is an intranasal formulation of synthetic 5-MeO-DMT and is currently being evaluated in a Phase 2 study for treatment-resistant depression. More details about the study can be found in the clinical trial registration link below.\", \"study title\": \"Treatment-resistant depression (TRD)|  BPL-003 (5-MeO-DMT)  \", \"phase\": \" Phase 2\", \"health issue\": \"Treatment-resistant depression \", \"product molecule substance\": \"BPL-003  \", \"lead substance substract\": \"5-MeO-DMT\"}, {\"lab\": \"MindMed \", \"study explanation\": \"MM-110, also known as 18-MC or zolunicant, is a non-hallucinogenic ibogaine derivative. MM-110 intended for use in opioid withdrawal and as a potential treatment of opioid use disorder and is set to be evaluated in a Phase 2a trial. Details about a completed Phase 1 study can be found in the clinical trial registration link below.\", \"study title\": \"Opioid Withdrawal  | MM-110 (18-MC)  \", \"phase\": \" Phase 2a\", \"health issue\": \"Opioid Withdrawal  \", \"product molecule substance\": \"MM-110  \", \"lead substance substract\": \"18-MC\"}, {\"lab\": \"MAPS PBC\", \"study explanation\": \"MAPS is evaluating MDMA-assisted group therapy in a Phase 2 trial as a potential treatment for PTSD. More details about the study can be found in the clinical trial registration link below.\", \"study title\": \"Post-traumatic stress disorder (PTSD)|  MDMA  \", \"phase\": \" Phase 2\", \"health issue\": \"Post-traumatic stress disorder \", \"product molecule substance\": \"MDMA \", \"lead substance substract\": \"MDMA  \"}, {\"lab\": \"MAPS PBC\", \"study explanation\": \"MAPS is evaluating MDMA-assisted psychotherapy in a Phase 2 study as a potential treatment for eating disorders (anorexia nervosa and binge eating disorder). More details about the study can be found in the clinical trial registration link below.\", \"study title\": \"Anorexia nervosa & Binge eating disorder |  MDMA  \", \"phase\": \" Phase 2\", \"health issue\": \"Anorexia nervosa & Binge eating disorder \", \"product molecule substance\": \"MDMA \", \"lead substance substract\": \"MDMA  \"}, {\"lab\": \"Usona Institute \", \"study explanation\": \"The Usona Institute is currently evaluating psilocybin-assisted therapy in a Phase 2 trial as a potential treatment for major depressive disorder, after receiving Breakthrough Therapy Status from the FDA. More details about the study can be found in the clinical trial registration link below.\", \"study title\": \"Major Depressive Disorder (MDD)  |  Psilocybin  \", \"phase\": \" Phase 2\", \"health issue\": \"Major Depressive Disorder   \", \"product molecule substance\": \"Psilocybin \", \"lead substance substract\": \"Psilocybin  \"}, {\"lab\": \"Tryp Therapeutics\", \"study explanation\": \"TRP-8802 is an orally-delivered synthetic psilocybin formulation set to be evaluated in a Phase 2 trial as a potential treatment for fibromyalgia. More details about the trial can be found in the clinical trial registration link below.\", \"study title\": \"Fibromyalgia  |  TRP-8802 (Psilocybin)  \", \"phase\": \" Phase 2a\", \"health issue\": \"Fibromyalgia  \", \"product molecule substance\": \"TRP-8802  \", \"lead substance substract\": \"Psilocybin\"}, {\"lab\": \"Compass Pathways \", \"study explanation\": \"COMP360 is a psilocybin formulation currently being evaluated in a Phase 2 trial for potential use in anorexia nervosa. More information about the study can be found in the clinical trial registration link below.\", \"study title\": \"Anorexia Nervosa  |  COMP360 (Psilocybin)  \", \"phase\": \" Phase 2\", \"health issue\": \"Anorexia Nervosa  \", \"product molecule substance\": \"COMP360  \", \"lead substance substract\": \"Psilocybin\"}, {\"lab\": \"Compass Pathways \", \"study explanation\": \"COMP360 is a psilocybin formulation currently being evaluated in a Phase II trial for potential use in post-traumatic stress disorder (PTSD). More details about the study can be found in the clinical trial registration link below.\", \"study title\": \"Post-traumatic stress disorder (PTSD)|  COMP360 (Psilocybin)  \", \"phase\": \" Phase 2\", \"health issue\": \"Post-traumatic stress disorder \", \"product molecule substance\": \"COMP360  \", \"lead substance substract\": \"Psilocybin\"}, {\"lab\": \"Braxia Scientific\", \"study explanation\": \"Braxia is evaluating psilocybin-assisted therapy in a Phase II trial for potential use in treatment-resistant depression. More details about the trial can be found in the clinical trial registration link below.\", \"study title\": \"Treatment-resistant depression (TRD)|  Psilocybin  \", \"phase\": \" Phase 2\", \"health issue\": \"Treatment-resistant depression \", \"product molecule substance\": \"Psilocybin \", \"lead substance substract\": \"Psilocybin  \"}, {\"lab\": \"Janssen \", \"study explanation\": \"SPRAVATO is an intranasal esketamine formulation being evaluated in a Phase 2 study as a potential treatment for symptoms of major depressive disorder including suicidal ideation, in participants 12 to less than 18 years of age. SPRAVATO has already received FDA approval for use in adults with treatment-resistant depression or acute suicidal ideation and behaviour in major depressive disorder. Please see theSPRAVATO labelfor more information.\", \"study title\": \"Major Depressive Disorder (MDD)  | Spravato (Esketamine)  \", \"phase\": \" Phase 2\", \"health issue\": \"Major Depressive Disorder   \", \"product molecule substance\": \"Spravato  \", \"lead substance substract\": \"Esketamine\"}, {\"lab\": \"Seelos Therapeutics\", \"study explanation\": \"SLS-002 is an intranasal racemic ketamine product currently being evaluated in a Phase 2 trial as a potential treatment for acute suicidal ideation and behaviour (ASIB) in major depressive disorder. More details about the ongoing trial can be found in the clinical trial registration link below.\", \"study title\": \"Acute Suicidal Ideation and Behaviour  (ASIB)  |  SLS-002 (Ketamine)  \", \"phase\": \" Phase 2\", \"health issue\": \"Acute Suicidal Ideation and Behaviour    \", \"product molecule substance\": \"SLS-002  \", \"lead substance substract\": \"Ketamine\"}, {\"lab\": \"MindMed \", \"study explanation\": \"As part of a deal with University Hospital Basel's Liechti Lab, MindMed has acquired the rights to an ongoing Phase II evaluating LSD as a potential treatment for cluster headaches. More details about the study can be found in the clinical trial registration link below.\", \"study title\": \"Cluster Headaches  |  LSD \", \"phase\": \" Phase 2\", \"health issue\": \"Cluster Headaches  \", \"product molecule substance\": \"LSD\", \"lead substance substract\": \"LSD \"}, {\"lab\": \"Incannex\", \"study explanation\": \"In partnership with Monash University, Incannex is evaluating psilocybin-assisted therapy in a Phase II trial as a potential treatment for generalized anxiety disorder. More details about the study can be found in the clinical trial registration link below.\", \"study title\": \"Generalized Anxiety Disorder (GAD)  |  Psilocybin  \", \"phase\": \" Phase 2\", \"health issue\": \"Generalized Anxiety Disorder   \", \"product molecule substance\": \"Psilocybin \", \"lead substance substract\": \"Psilocybin  \"}, {\"lab\": \"Clexio Biosciences\", \"study explanation\": \"CLE-100 is a formulation of oral esketamine currently being evaluated in a Phase 2 study as a potential treatment for major depressive disorder. More details about the trial can be found in the clinical trial registration link below.\", \"study title\": \"Major Depressive Disorder (MDD)  |  CLE-100 (Esketamine)  \", \"phase\": \" Phase 2\", \"health issue\": \"Major Depressive Disorder   \", \"product molecule substance\": \"CLE-100  \", \"lead substance substract\": \"Esketamine\"}, {\"lab\": \"Clairvoyant\", \"study explanation\": \"Clairvoyant is evaluating psilocybin-assisted therapy in a Phase 2 trial as a potential treatment for alcohol use disorder. More details about the study can be found in the clinical trial registration link below.\", \"study title\": \"Alcohol Use Disorder (AUD) |  Psilocybin  \", \"phase\": \" Phase 2\", \"health issue\": \"Alcohol Use Disorder  \", \"product molecule substance\": \"Psilocybin \", \"lead substance substract\": \"Psilocybin  \"}, {\"lab\": \"Ceruvia Lifesciences\", \"study explanation\": \"SYNP-101 is a synthetic form of psilocybin being developed as a potential treatment for obsessive compulsive disorder. SYNP-101 is currently being evaluated in a Phase 2 trial. More details about an associated trial can be found in the clinical trial registration link below.\", \"study title\": \"Obsessive Compulsive Disorder (OCD) |  SYNP-101 (Psilocybin)  \", \"phase\": \" Phase 2\", \"health issue\": \"Obsessive Compulsive Disorder  \", \"product molecule substance\": \"SYNP-101  \", \"lead substance substract\": \"Psilocybin\"}, {\"lab\": \"Psyence\", \"study explanation\": \"Psyence is set to evaluate psilocybin-assisted therapy in a Phase 2 study for the treatment of adjustment disorder due to an incurable cancer diagnosis in a palliative care context.\", \"study title\": \"Adjustment Disorder  |  Psilocybin  \", \"phase\": \" Phase 2\", \"health issue\": \"Adjustment Disorder  \", \"product molecule substance\": \"Psilocybin \", \"lead substance substract\": \"Psilocybin  \"}, {\"lab\": \"Beckley Psytech \", \"study explanation\": \"BPL-003 is an intranasal formulation of synthetic 5-MeO-DMT and is currently being evaluated in a Phase 2 study for alcohol use disorder. More details about the study can be found in the clinical trial registration link below.\", \"study title\": \"Alcohol Use Disorder (AUD)  |  BPL-003 (5-MeO-DMT)  \", \"phase\": \" Phase 2\", \"health issue\": \"Alcohol Use Disorder   \", \"product molecule substance\": \"BPL-003  \", \"lead substance substract\": \"5-MeO-DMT\"}, {\"lab\": \"SmallPharma\", \"study explanation\": \"Top-line results from Small Pharma's Phase IIa trial of DMT for MDDare now available.\", \"study title\": \"Major Depressive Disorder (MDD) |  SPL026 (DMT)   (Completed)\", \"phase\": \" Phase 2a\", \"health issue\": \"Major Depressive Disorder  \", \"product molecule substance\": \"SPL026   \", \"lead substance substract\": \"DMT)   (Completed\"}, {\"lab\": \"MindMed \", \"study explanation\": \"MM-120 is a formulation of LSD being evaluated in a Phase 2 trial as a potential treatment for attention deficit hyperactivity disorder (ADHD) in adults. More details about the trial can be found in the clinical trial registration link below.\", \"study title\": \"Attention Deficit Disorder (ADHD)  |  MM120 (LSD)  \", \"phase\": \" Phase 2a\", \"health issue\": \"Attention Deficit Disorder   \", \"product molecule substance\": \"MM120  \", \"lead substance substract\": \"LSD\"}, {\"lab\": \"Cybin\", \"study explanation\": \"CYB003 is an orally dissolving tablet formulation of an unknown deuterated psilocybin analog currently being evaluated in a Phase 1/2 trial for major depressive disorder. More details about the study can be found in the clinical trial registration below.\", \"study title\": \"Major Depressive Disorder (MDD)  |  CYB003 (Deuterated Psilocybin Analog)  /2\", \"phase\": \" Phase 1\", \"health issue\": \"Major Depressive Disorder   \", \"product molecule substance\": \"CYB003  \", \"lead substance substract\": \"Deuterated Psilocybin Analog\"}, {\"lab\": \"DemeRx \", \"study explanation\": \"DMX-1002 is an ibogaine formulation set to be evaluated in a combined Phase I/II study as a potential treatment for opioid use disorder (specifically for medically-assisted detoxification). DemeRx is one of atai Life Sciences' drug development programs. More details about the Phase I/II study can be found in the clinical trial registration link below.\", \"study title\": \"Opiate Withdrawal Syndrome  |  DMX-1002 (Ibogaine)  /2\", \"phase\": \" Phase 1\", \"health issue\": \"Opiate Withdrawal Syndrome  \", \"product molecule substance\": \"DMX-1002  \", \"lead substance substract\": \"Ibogaine\"}, {\"lab\": \"Beckley Psytech \", \"study explanation\": \"ELE-001 is an intravenous (IV) formulation of psilocin, the active metabolite of psilocybin, being developed as a possible treatment for depression. ELE-001 was acquired by Beckley Psytech from Eleusis Therapeutics in October 2022, who had begun a Phase 1/2 trial. More details about the trial can be found in the clinical trial registration link below.\", \"study title\": \"Major Depressive Disorder (MDD)  |  ELE-101 (Psilocin)  /2\", \"phase\": \" Phase 1\", \"health issue\": \"Major Depressive Disorder   \", \"product molecule substance\": \"ELE-101  \", \"lead substance substract\": \"Psilocin\"}, {\"lab\": \"Algernon Pharmaceuticals\", \"study explanation\": \"AP-188 is a sub-hallucinogenic, IV DMT formulation being developed as a possible treatment of ischemic stroke and for post-stroke rehabilitation. AP-188 is currently being evaluated in a Phase 1 trial.\", \"study title\": \"Ischemic Stroke  |  AP-188 (DMT)  \", \"phase\": \" Phase 1\", \"health issue\": \"Ischemic Stroke  \", \"product molecule substance\": \"AP-188  \", \"lead substance substract\": \"DMT\"}, {\"lab\": \"biomind labs\", \"study explanation\": \"BMND01 is a liquid inhaled formulation of DMT that was evaluated in a Phase 1 study. More details about the study can be found in the clinical trial registration link below.\", \"study title\": \"Healthy Volunteers |  BMND01 (DMT)  \", \"phase\": \" Phase 1\", \"health issue\": \"Healthy Volunteers \", \"product molecule substance\": \"BMND01  \", \"lead substance substract\": \"DMT\"}, {\"lab\": \"Optimi Health\", \"study explanation\": \"MELOCIN is a naturally derived Psilocybe extract set to be evaluated in a Phase I trial. More details about the trial can be found in the clinical trial registration link below.\", \"study title\": \"Healthy Volunteers  |  Psilocybin  \", \"phase\": \" Phase 1\", \"health issue\": \"Healthy Volunteers  \", \"product molecule substance\": \"Psilocybin \", \"lead substance substract\": \"Psilocybin  \"}, {\"lab\": \"MindMed \", \"study explanation\": \"MM-402 is R(-)-MDMA, an isomer of MDMA, as a potential treatment for social anxiety associated with Autism Spectrum Disorder. R-MDMA is being evaluated in a Phase I trial comparing it S-MDMA and racemic MDMA (R/S MDMA). More details about the study can be found in the clinical trial registration link below.\", \"study title\": \"Autism Spectrum Disorder (ASD)  |  MM-402 (R(-)-MDMA) \", \"phase\": \" Phase 1\", \"health issue\": \"Autism Spectrum Disorder   \", \"product molecule substance\": \"MM-402 \", \"lead substance substract\": \"R(-)-MDMA\"}, {\"lab\": \"MindMed \", \"study explanation\": \"MindMed is evaluating mescaline in a Phase I trial, though the intended indication(s) remains unclear. More details about the trial can be found in the clinical trial link below.\", \"study title\": \"Healthy Volunteers  |  Mescaline  \", \"phase\": \" Phase 1\", \"health issue\": \"Healthy Volunteers  \", \"product molecule substance\": \"Mescaline \", \"lead substance substract\": \"Mescaline  \"}, {\"lab\": \"Reunion \", \"study explanation\": \"RE104 is isoprocin glutarate, a prodrug of 4-HO-DiPT. RE104 is currently being evaluated in a Phase 1 trial and is intended for use in postpartum depression. More details about the study can be found in the clinical trial registration link below.\", \"study title\": \"Healthy Volunteers  |  RE104 (4-HO-DiPT; Isoprocin Glutarate)  \", \"phase\": \" Phase 1\", \"health issue\": \"Healthy Volunteers  \", \"product molecule substance\": \"RE104  \", \"lead substance substract\": \"4-HO-DiPT; Isoprocin Glutarate\"}, {\"lab\": \"Ceruvia Lifesciences\", \"study explanation\": \"NYPRG-101 is a non-hallucinogenic LSD analog, more commonly known as 2-Bromo-LSD or BOL-148. NYPRG-101 is currently in Phase I and is being evaluated as a potential treatment of cluster headaches.\", \"study title\": \"Cluster Headaches |  NYPRG-101 (BOL-148)  \", \"phase\": \" Phase 1\", \"health issue\": \"Cluster Headaches \", \"product molecule substance\": \"NYPRG-101  \", \"lead substance substract\": \"BOL-148\"}, {\"lab\": \"GH Research\", \"study explanation\": \"GH002 is an injectable formulation of 5-MeO-DMT, a short-acting psychedelic. GH002 is set to be evaluated in a Phase 1 study.\", \"study title\": \"Healthy Volunteers  |  GH002 (5-MeO-DMT)  \", \"phase\": \" Phase 1\", \"health issue\": \"Healthy Volunteers  \", \"product molecule substance\": \"GH002  \", \"lead substance substract\": \"5-MeO-DMT\"}, {\"lab\": \"MindSet\", \"study explanation\": \"MSP-1014 is a deuterated prodrug of psilocybin set to be evaluated in a Phase 1 study. MSP-1014 is intended as a potential treatment of major depressive disorder.\", \"study title\": \"Major Depressive Disorder (MDD)  |  MSP-1014 (Deuterated Psilocybin Prodrug)  \", \"phase\": \" Phase 1\", \"health issue\": \"Major Depressive Disorder   \", \"product molecule substance\": \"MSP-1014  \", \"lead substance substract\": \"Deuterated Psilocybin Prodrug\"}, {\"lab\": \"EmpathBio \", \"study explanation\": \"EmpathBio is developing EMP-01, an MDMA-derivative for use in entactogen-assisted psychotherapy to treat post-traumatic stress disorder. EMP-01 is currently being evaluated in a Phase 1 trial. More details about the study can be found in the clinical trial registration link below. EmpathBio is one of atai Life Sciences' drug development programs.\", \"study title\": \"Post-traumatic stress disorder (PTSD)|  EMP-01 (MDMA Derivative)  \", \"phase\": \" Phase 1\", \"health issue\": \"Post-traumatic stress disorder \", \"product molecule substance\": \"EMP-01  \", \"lead substance substract\": \"MDMA Derivative\"}, {\"lab\": \"SmallPharma\", \"study explanation\": \"SPL026 is a formulation of DMT being developed as a potential treatment for major depressive disorder. SPL026 is currently being evaluated in a Phase 1 study to compare the effects when administered intravenously (IV) or intramuscularly (IM). Small Pharma was granted an Innovation Passport Designation for SPL026 from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA). More details about the study can be found in the clinical trial registration link below.\", \"study title\": \"Major Depressive Disorder (MDD)  |  SPL029 (DMT)  \", \"phase\": \" Phase 1\", \"health issue\": \"Major Depressive Disorder   \", \"product molecule substance\": \"SPL029  \", \"lead substance substract\": \"DMT\"}, {\"lab\": \"SmallPharma\", \"study explanation\": \"SPL028 is a formulation of an unknown deuterated DMT molecule. SPL028 is currently being evaluated in a Phase 1 trial to compare the effects when administered intravenously (IV) or intramuscularly (IM).\", \"study title\": \"Healthy Volunteers  |  SPL028 (Deuterated DMT)  \", \"phase\": \" Phase 1\", \"health issue\": \"Healthy Volunteers  \", \"product molecule substance\": \"SPL028  \", \"lead substance substract\": \"Deuterated DMT\"}, {\"lab\": \"Viridia Life Sciences\", \"study explanation\": \"VLS-01 is a formulation of DMT intended for potential use in treatment-resistant depression. VLS-01 is currently being evaluated in a Phase 1 trial to compare the effects when administered intravenously (IV) or buccally.\", \"study title\": \"Treatment-resistant depression (TRD)|  VLS-01 (DMT)  \", \"phase\": \" Phase 1\", \"health issue\": \"Treatment-resistant depression \", \"product molecule substance\": \"VLS-01  \", \"lead substance substract\": \"DMT\"}, {\"lab\": \"Bright Minds Biosciences\", \"study explanation\": \"BMB-101 is an unknown 5-HT2C agonist being evaluated in a Phase 1 trial for potential use in Dravet Syndrome, opioid use disorder, and binge eating disorder. More details about the study can be found in the clinical trial registration link below.\", \"study title\": \"Healthy Volunteers  |  BMB-101 (5-HT2C Agonist)  \", \"phase\": \" Phase 1\", \"health issue\": \"Healthy Volunteers  \", \"product molecule substance\": \"BMB-101  \", \"lead substance substract\": \"5-HT2C Agonist\"}, {\"lab\": \"Diamond Therapeutics\", \"study explanation\": \"Diamond Therapeutics' lead programme is the development of low-dose psilocybin for the potential treatment of undisclosed anxiety disorders. Diamond completed a Phase 1 trial in late 2022. Previously reported preclinical trial results can befound here.\", \"study title\": \"Anxiety Disorders  |  Psilocybin  \", \"phase\": \" Phase 1\", \"health issue\": \"Anxiety Disorders  \", \"product molecule substance\": \"Psilocybin \", \"lead substance substract\": \"Psilocybin  \"}, {\"lab\": \"Ceruvia Lifesciences\", \"study explanation\": \"NYPRG-101 is a non-hallucinogenic LSD analog, more commonly known as 2-Bromo-LSD or BOL-148. NYPRG-101 is currently in Phase I and is being evaluated as a potential treatment of migraines.\", \"study title\": \"Migraines  |  NYPRG-101 (BOL-148)  \", \"phase\": \" Phase 1\", \"health issue\": \"Migraines  \", \"product molecule substance\": \"NYPRG-101  \", \"lead substance substract\": \"BOL-148\"}, {\"lab\": \"Delix (Colour)\", \"study explanation\": \"Delix Therapeutics is developing a number of non-hallucinogenic psychedelic compounds, referred to as psychoplastogens, and is currently in the preclinical stage of development. Details about one of Delix Therapeutics' lead compounds \\\"DLX-7\\\" or Tabernanthalog (TBG), an ibogaine analog, werepublished hereandhere. Details about another compound, \\\"DLX-1\\\", also known as AAZ-A-154, werepublished here.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": \"Treatment-resistant depression  | cognitive impairment in schizophrenia | neurodegeneration\", \"product molecule substance\": \"Tabernanthalog (TBG)\", \"lead substance substract\": \"Tabernanthalog (TBG)\"}, {\"lab\": \"Cybin\", \"study explanation\": \"CYB003 is an orally dissolving tablet formulation of an unknown deuterated psilocybin analog currently in the preclinical stage of development, intended as a treatment for alcohol use disorder.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": \"Alcohol Use Disorder \", \"product molecule substance\": \"psilocybin analog\", \"lead substance substract\": \"psilocybin analog\"}, {\"lab\": \"Ceruvia Lifesciences\", \"study explanation\": \"NYPRG-101 is a non-hallucinogenic LSD analog, more commonly known as 2-Bromo-LSD or BOL-148. NYPRG-101 is currently in the preclinical stage and is being evaluated as a potential treatment of both opioid and alcohol use disorder.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": \"Alcohol Use Disorder  |Opioid Use Disorder\", \"product molecule substance\": \"LSD analog\", \"lead substance substract\": \"LSD analog\"}, {\"lab\": \"Bexson Biomedical\", \"study explanation\": \"BB-106 is a ketamine formulation delivered subcutaneously via a wearable medical pump. BB-106 is currently in the preclinical stage and is being evaluated as a potential treatment of depression, as well as a variety of pain-related indications including post-operative pain, cancer pain, and Complex Regional Pain Syndrome.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": \"Depression | Pain\", \"product molecule substance\": \"Ketamine\", \"lead substance substract\": \"Ketamine\"}, {\"lab\": \"Gilgamesh\", \"study explanation\": \"GM-1020, a less-dissociative, oral arylcyclohexamine NMDA antagonist molecule, as a potential treatment for depression;\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": \"Depression\", \"product molecule substance\": \"GM-1020\", \"lead substance substract\": \"nan\"}, {\"lab\": \"Gilgamesh\", \"study explanation\": \"GM-2505, a 5-HT2A agonist and 5-HT releaser intended as a potential treatment for depression;\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": \"Depression\", \"product molecule substance\": \"GM-2505\", \"lead substance substract\": \"nan\"}, {\"lab\": \"Gilgamesh\", \"study explanation\": \"GM-300X, an ibogaine analogue intended as a potential treatment of opioid use disorder;\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": \"Opioid Use Disorder\", \"product molecule substance\": \"GM-300X\", \"lead substance substract\": \"nan\"}, {\"lab\": \"Gilgamesh\", \"study explanation\": \"GM-200X, a non-hallucinogenic 5-HT2A agonist intended as a potential treatment for attention deficit hyperactivity disorder (ADHD).\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": \"Attention Deficit Disorder \", \"product molecule substance\": \"GM-200X\", \"lead substance substract\": \"nan\"}, {\"lab\": \"Terran Biosciences \", \"study explanation\": \"Terran Biosciences is developing a number of unknown compounds to treat neurological and psychiatric indications, having acquired or licensed assets fromConcert Pharmaceuticals,Blumentech,Sanofi, andUniversity of Maryland, Baltimore.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": null, \"product molecule substance\": null, \"lead substance substract\": \"nan\"}, {\"lab\": \"Freedom Biosciences\", \"study explanation\": \"Freedom Biosciences is in the preclinical stages of developing a combination therapy consisting of ketamine and an mTORC1 inhibitor (presumed to be rapamycin) for the treatment of major depressive disorder.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": \"Major Depressive Disorder \", \"product molecule substance\": \"Ketamine\", \"lead substance substract\": \"Ketamine\"}, {\"lab\": \"MindSet\", \"study explanation\": \"Mindset Pharma is currently in the preclinical stages of development for a number of compounds including MSP-2020 and MSP-2003, two unknown 5-HT2A agonists. Mindset Pharma is collaborating with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": null, \"product molecule substance\": null, \"lead substance substract\": \"nan\"}, {\"lab\": \"Arcadia Medicine \", \"study explanation\": \"AM-1002 is an unknown phenethylamine empathogen in the preclinical stage of development, intended for use in PTSD.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": \"Post-traumatic stress disorder \", \"product molecule substance\": \"AM-1002\", \"lead substance substract\": \"nan\"}, {\"lab\": \"Lophora\", \"study explanation\": \"LPH-5 is an unknown 5-HT2A agonist currently in the preclinical stage and is being investigated for potential use in treatment-resistant depression. Lophora anticipates initiating a Phase I study of LPH-5 in 2023.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": \"Treatment-resistant depression \", \"product molecule substance\": \"LPH-5\", \"lead substance substract\": \"nan\"}, {\"lab\": \"Psilera Bioscience\", \"study explanation\": \"Two DMT analogues, PSIL-001 and PSIL-002.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": null, \"product molecule substance\": \"DMT\", \"lead substance substract\": \"DMT\"}, {\"lab\": \"Transcend Therapeutics \", \"study explanation\": \"Methylone.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": \"Major Depressive Disorder \", \"product molecule substance\": \"Methylone\", \"lead substance substract\": \"Methylone\"}, {\"lab\": \"Bright Minds Biosciences\", \"study explanation\": \"Bright Minds has a number of 5-HT2A and combined 5-HT2A + 5-HT2C agonist molecules in the preclinical stage of development. The 5-HT2A compounds are being evaluated for use in depression and post-traumatic stress disorder. The combined 5-HT2A + 5-HT2C compounds are being evaluated for use in several chronic pain disorders, including cluster headaches and chemotherapy-induced peripheral neuropathy.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": \"Major Depressive Disorder  | chronic pain disorders\", \"product molecule substance\": \" 5-HT2A\", \"lead substance substract\": \"nan\"}, {\"lab\": \"CaamTech \", \"study explanation\": \"CaaMTech has a collaborative preclinical drug development program with the Designer Drug Research Unit at the National Institute on Drug Abuse Intramural Research Program to help determine which of their compounds are the most promising to proceed to human trials. These include, but are not limited to:\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": null, \"product molecule substance\": null, \"lead substance substract\": \"nan\"}, {\"lab\": \"GH Research\", \"study explanation\": \"GH003 is an intranasal formulation of 5-MeO-DMT, a short-acting psychedelic. GH003 is currently in the preclinical stage for an unknown indication.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": \"Treatment-resistant depression \", \"product molecule substance\": null, \"lead substance substract\": \"5-MeO-DMT\"}, {\"lab\": \"SmallPharma\", \"study explanation\": \"SPL029 is an unknown oral tryptamine 5-HT2A agonist molecule currently in the preclinical stage for an unknown indication.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": \"Major Depressive Disorder \", \"product molecule substance\": \"SPL029\", \"lead substance substract\": \"nan\"}, {\"lab\": \"Neonmind \", \"study explanation\": \"NEO-001 is a synthetic form of psilocybin in the preclinical stages of development as a potential treatment for weight loss. NeonMind is currently conducting a preclinical trial with psilocybin as a potential treatment for obesity.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": \"Obesity\", \"product molecule substance\": \"NEO-001\", \"lead substance substract\": \"Psilocybin\"}, {\"lab\": \"Journey Colab\", \"study explanation\": \"JOUR-5700 is a synthetic form of mescaline in the preclinical stages of development for the potential treatment of alcohol use disorder.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": \"Alcohol Use Disorder \", \"product molecule substance\": \"JOUR-5700 \", \"lead substance substract\": \"Mescaline\"}, {\"lab\": \"Tactogen\", \"study explanation\": \"Tactogen has a number of unknown entactogen molecules in the preclinical stage of development.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": null, \"product molecule substance\": null, \"lead substance substract\": \"nan\"}, {\"lab\": \"BetterLife Pharma\", \"study explanation\": \"BETR-001 is a non-hallucinogenic LSD derivative molecule, more commonly known as 2-Bromo-LSD or BOL-148. BETR-001 is currently in the preclinical stage and is being investigated for potential use in treatment-resistant depression, as well as migraines.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": \"Treatment-resistant depression  | Migraines\", \"product molecule substance\": \"2-Bromo-LSD\", \"lead substance substract\": \"LSD\"}, {\"lab\": \"Lobe Sciences \", \"study explanation\": \"L-131.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": null, \"product molecule substance\": null, \"lead substance substract\": \"nan\"}, {\"lab\": \"Sensorium Therapeutics \", \"study explanation\": \"SENS-01 is an unknown molecule currently in the preclinical stage of development, intended for use in anxiety and depression.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": \"Major Depressive Disorder  | Anxiety\", \"product molecule substance\": \"SENS-01\", \"lead substance substract\": \"nan\"}, {\"lab\": \"Clearmind Medicine\", \"study explanation\": \"CMND-100 is a synthetic form of MEAI\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": null, \"product molecule substance\": \"MEAI\", \"lead substance substract\": \"nan\"}, {\"lab\": \"Tryp Therapeutics\", \"study explanation\": \"TRP-8802 is an orally-delivered synthetic psilocybin formulation currently in the preclinical stage of being evaluated as a potential treatment for phantom limb pain.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": \"phantom limb pain\", \"product molecule substance\": \" TRP-8802\", \"lead substance substract\": \"Psilocybin\"}, {\"lab\": \"Lusaris Therapeutics \", \"study explanation\": \"LSR-1019 is a sublingual formulation of 5-MeO-DMT currently in the preclinical stage, intended for use in treatment-resistant depression.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": \"Treatment-resistant depression \", \"product molecule substance\": \"LSR-1019\", \"lead substance substract\": \"DMT\"}, {\"lab\": \"Empyrean \", \"study explanation\": \"PsiD+.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": \"central nervous system disorders\", \"product molecule substance\": \"Psilocybin\", \"lead substance substract\": \"Psilocybin\"}, {\"lab\": \"Mindstate Design\", \"study explanation\": \"MSD-100.\", \"study title\": null, \"phase\": \"Preclinical\", \"health issue\": null, \"product molecule substance\": \"Psilocybin\", \"lead substance substract\": \"Psilocybin\"}]}}, {\"mode\": \"vega-lite\"});\n",
       "</script>"
      ],
      "text/plain": [
       "alt.Chart(...)"
      ]
     },
     "execution_count": 115,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "alt.Chart(ftr_atom).mark_bar().encode(\n",
    "    x='phase',\n",
    "    y='count()'\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "base",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.12"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
